ࡱ> #` ~bjbjmm 6N       4, 4Bh0`M)}p "    4'dyyyyyyy$hwy j2e " j2j2y   |Z*C*C*Cj2  y*Cj2y*C*Cufw  Ti  K*'"9\g$i|<)}hDS~;SHTiS Ti+-&*C./+++yy^A+++)}j2j2j2j2`M`M`MD`M`M`MDL $p (         INSTITUTIONAL BIOSAFETY COMMITTEE Protocol Submission Form For new protocols or those involving the use of recombinant DNA in research INSTRUCTIONS (indicate type of submission): All submissions must be typed. Submit to Research Services, Granada Center Suite 400. If off campus, submit to 6439 N. Sheridan, Suite 400, Chicago, IL 60626. Call 773 508-2689 for additional forms and information. Keep a copy for your records. **To indicate a checked box, double click the box and indicate checked as the default value.  FORMCHECKBOX  rDNA submissions - submit the original application plus 11 copies to the address above.  FORMCHECKBOX  Transgenic/Knockout rodent submission (purchase or transfer only) complete Sections I through V and Sections IX through X. Submit one original and one copy of the application. SECTION I. GENERAL PROJECT DETAILS Investigator Name:  FORMTEXT       Department:  FORMTEXT       Campus Address:  FORMTEXT       Phone:  FORMTEXT       Email:  FORMTEXT       Fax:  FORMTEXT       Primary Contact:  FORMTEXT       Campus Address:  FORMTEXT       Email:  FORMTEXT       Phone:  FORMTEXT       Title of Protocol:  FORMTEXT       Funding:  FORMCHECKBOX  Internally funded  FORMCHECKBOX  Externally funded. Source:  FORMTEXT       Grant/sponsor number:  FORMTEXT        FORMCHECKBOX  New Study  FORMCHECKBOX  Ongoing Research Project Title:  FORMTEXT       Sponsor(s) of the research:  FORMTEXT        FORMCHECKBOX  Human Subjects Research (IRB) Protocol number:  FORMTEXT       Most recent approval date:  FORMTEXT        FORMCHECKBOX  Animal Research (IACUC)  FORMCHECKBOX  Previously approved: Protocol number:  FORMTEXT       Most recent approval date:  FORMTEXT        FORMCHECKBOX  Pending Date submitted:  FORMTEXT       SECTION II. RESEARCH SUMMARY Please summarize the proposed research. Limit your discussion to one page. Note that  See Attached with the attachment of a grant narrative is unacceptable. Provide a basic description and rationale for your project.  FORMTEXT       Describe what systems you plan to use, including any animal work, your endpoint, and what type of manipulations you plan to use to achieve that goal.  FORMTEXT       If the experiment is conducted in more than one room, or if different phases are going to be conducted at different Biosafety Levels, describe each component separately, listing lab numbers and procedures specific to each.  FORMTEXT       SECTION III. RISK ASSESSMENT  FORMCHECKBOX  Whole Plants Species:  FORMTEXT        FORMCHECKBOX  Transactive or infectious proteins; Protein:  FORMTEXT       Agent:  FORMTEXT       Cellular Target:  FORMTEXT       Hazards of Exposure:  FORMTEXT        FORMCHECKBOX  This project involves the purchase or transfer of transgenic/knockout rodents at Biosafety Level 1  PROCEED TO SECTION IV  FORMCHECKBOX  This project involves infectious agents, plasmid and/or viral vectors PROCEED TO SECTION V  FORMCHECKBOX  This project involves the purchase or transfer of transgenic/knockout rodents as well as the manipulation of other recombinant materials, or the generation of transgenic/knockout rodents COMPLETE ENTIRE APPLICATION.  FORMCHECKBOX  This project involves transgenic/knockout rodents as well as human/primate cell lines COMPLETE SECTIONS IV, VII, VIII, IX AND X. PLEASE NOTE A LABORATORY INSPECTION FROM THE BIOSAFETY OFFICER WILL BE REQUIRED PRIOR TO FINAL APPROVAL. SECTION IV. TRANSGENIC/KNOCKOUT RODENT STUDIES For each rodent, list the specifics regarding each animal strain utilized for this research project. StrainVendor/ OriginGene productKnockout (KO) or Transgene (T)Oncogenic? (yes/no) Known Hazard? (Yes/No)TAT* fusion? *Membrane transduction domain (Yes/No) Knock-out of gene product or transgeneTissue specific? (Yes/No)Regulatable (R) / Conditional (C)Inducing agent? (Yes/No)Hazards? (Yes4/No) FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       Most work with transgenic and knockout animals will be conducted at Biosafety Level 1. However, certain vectors used to produce the transgenic or knockout may necessitate a higher Biosafety level (e.g., transgenic mice derived from lentivirus-based vectors). If this is the case, please list the gene product/vector  FORMTEXT       and its associated higher Biosafety level:  FORMTEXT       Describe potential hazard for any gene product (if marked  Yes above):  FORMTEXT       Describe TAT fusion for any gene product. TAT fusions are minimum BL2 agents. (if marked  Yes above):  FORMTEXT       4 Describe hazards of the knockout of the gene product or transgene (if marked  Yes above):  FORMTEXT       Does this project also involve the use of infectious agents, plasmids, and/or viral vectors?  FORMCHECKBOX  Yes Proceed to Section V.  FORMCHECKBOX  No Does this project involve the use of human/primate cell lines?  FORMCHECKBOX  Yes Proceed to Section VII.  FORMCHECKBOX  No Proceed to Section IX. SECTION V. SELECT AGENTS AND TOXINS  FORMCHECKBOX  I am not using any select agents or toxins  FORMCHECKBOX  I am using the following selects agents or toxins: VIRUSESFUNGI FORMCHECKBOX Crimean-Congo (BL-4) FORMCHECKBOX Coccidioides immitis (BL-3) FORMCHECKBOX Eastern Equine Encephalitis virus (BL-2) FORMCHECKBOX Coccidiodes posadasii (BL-3) FORMCHECKBOX Ebola viruses (BL-4) FORMCHECKBOX Hendra virus (BL-4)TOXINS (29 CFR 1910.1450 and 1910.1200) FORMCHECKBOX Lassa fever virus (BL-4) FORMCHECKBOX Abrin FORMCHECKBOX Marburg virus (BL-4) FORMCHECKBOX Botulinum neurotoxins FORMCHECKBOX Rift Valley fever virus (BL-3) FORMCHECKBOX C. perfringens e toxinSouth American haemorrhagic fever viruses: (BL-4) FORMCHECKBOX Conotoxins FORMCHECKBOX Flexal FORMCHECKBOX Guanarito FORMCHECKBOX Junin FORMCHECKBOX Machupo FORMCHECKBOX Sabia FORMCHECKBOX DiacetoxyscirpenolTick-borne encephalitis complex (flavi) viruses: (BL-4) FORMCHECKBOX Ricin FORMCHECKBOX Central European encephalitis FORMCHECKBOX Far Eastern encephalitis FORMCHECKBOX Saxitoxin FORMCHECKBOX Russian spring/summer encephailits FORMCHECKBOX Kyasanur forest disease FORMCHECKBOX Shigatoxin FORMCHECKBOX Omsk hemorrhagic fever FORMCHECKBOX Shiga-like ribosome inactivating proteins FORMCHECKBOX Variola major virus (Smallpox virus) (BL-4, Restricted) FORMCHECKBOX Staphylococcal enterotoxins FORMCHECKBOX Variola minor virus (Alastrim) (BL-4, Restricted) FORMCHECKBOX Tetrodotoxin FORMCHECKBOX Venezuelan Equine Encephalitis virus (BL-3) FORMCHECKBOX T-2 toxin FORMCHECKBOX Cercopithecine herpesvirus 1 (Herpes B virus) (BL-3/4)BACTERIA FORMCHECKBOX Monkeypox virus (BL-3, BL-2 if vaccinated) FORMCHECKBOX Bacillus anthracis (BL-3) FORMCHECKBOX Brucella abortus, B. melitensis, B., suis (BL-3)USDA PATHOGENS FORMCHECKBOX Burkholderia (Pseudomonas) mallei (BL-3) FORMCHECKBOX African Horse Sickness Virus FORMCHECKBOX Burkholderia (Pseudomonas) psuedomallei (BL-3) FORMCHECKBOX African Swine Fever Virus FORMCHECKBOX Clostridium botulinum (BL-3) FORMCHECKBOX Akabane Virus FORMCHECKBOX Francisella tularensis (BL-3 if vaccinated) FORMCHECKBOX Avian Influenza Virus (highly pathogenic) FORMCHECKBOX Yersinia pestis (BL-3) FORMCHECKBOX Blue Tongue Virus (exotic) FORMCHECKBOX Camel Pox VirusPLANT PATHOGENS FORMCHECKBOX Classical Swine Fever Virus FORMCHECKBOX Liberobacter africanus FORMCHECKBOX Cowdria ruminatum (heartwater) FORMCHECKBOX Liberobacter asiaticus FORMCHECKBOX Foot & Mouth Disease Virus FORMCHECKBOX Peronosclerospora philippinensis FORMCHECKBOX Goat Pox Virus FORMCHECKBOX Phakospora pachyrhizi FORMCHECKBOX Japanese Encephalitis Virus FORMCHECKBOX Plum Pox Potyvirus FORMCHECKBOX Lumpy Skin Disease Virus FORMCHECKBOX Ralstonia solanacearum race 3, biovar 2 FORMCHECKBOX Malignant Catarrhal Fever Virus FORMCHECKBOX Schlerophthora rayssiae var zeae FORMCHECKBOX Menangle Virus FORMCHECKBOX Synchytrium endobioticum FORMCHECKBOX Newcastle Disease Virus (VVND) (BL-2) FORMCHECKBOX Xanthomonas oryzae FORMCHECKBOX Nipah Virus (BL-4) FORMCHECKBOX Xylella fastidiosa (citrus variegated chlorosis strain) FORMCHECKBOX Peste Des Petits Ruminants Virus FORMCHECKBOX Rinderpest Virus FORMCHECKBOX Sheep Pox VirusMany of the USDA Animal and Plant Pathogens have specific bio-containment requirements. Please contact the Biosafety Manager or the USDA for details FORMCHECKBOX Swine Vesicular Disease Virus FORMCHECKBOX Vesicular Stomatitis Virus (exotic) (BL-3) FORMCHECKBOX Mycoplasma capricolum/ M.F38/M. mycoides capri FORMCHECKBOX Mycoplasma mycoides mycoides FORMCHECKBOX Bovine Spongiform Encephalopathy Agent (BL-3)RICKETTSIAE FORMCHECKBOX Coxiella burnetii (BL-3) FORMCHECKBOX Rickettsia prowazekii (BL-3) FORMCHECKBOX Rickettsia rickettsii (BL-3) SECTION VI. RECOMBINANT DNA/VECTOR STUDIES 1. Please describe the species/source of rDNA(s):  FORMCHECKBOX  Organism  FORMTEXT       Literature citation if available:  FORMTEXT        FORMCHECKBOX  Clone bank  FORMTEXT       Literature citation if available:  FORMTEXT       2. Please list and describe the nature of the rDNA(s): Genes/Genomic DNA/cDNA/Other Mutated Gene (yes/no)?Oncogene (yes/no)? Potentially Harmful (explain)? FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT       3. Will the experimental procedures involve the deliberate transfer of a drug resistance trait to microorganisms and thus compromise the use of drugs commonly used to control disease in humans, veterinary medicine, or agriculture?  FORMCHECKBOX  Yes, describe  FORMTEXT        FORMCHECKBOX  No 4. Are plasmid vectors used in this study? Note: Attach maps for any non-commercial or custom-made plasmid vectors, or when changes have been made to the vector backbone.  FORMCHECKBOX  Yes, describe  FORMTEXT        FORMCHECKBOX  No 5. Are viral vectors used in this study? Note: Attach maps for any non-commercial or custom-made viral vectors, or when changes have been made to the vector backbone.  FORMCHECKBOX  Yes, describe  FORMTEXT        FORMCHECKBOX  No - continue to question 6. 5a. Are you using any helper viruses or packaging cell lines?  FORMCHECKBOX  Yes, describe  FORMTEXT        FORMCHECKBOX  No 5b. If you are using a virus, is it replication competent? Note: Adenoviruses are always considered replication competent.  FORMCHECKBOX  Yes  FORMCHECKBOX  No, describe validation tests to confirm replication incompetence:  FORMTEXT       5c. Are you using a lentiviral vector system (it must be a 3rd generation system)?  FORMCHECKBOX  Yes, check the appropriate box to indicate how you will acquire the lentiviral vector  FORMCHECKBOX  Produce in IU Vector Production Facility  FORMCHECKBOX  Produce in own laboratory  FORMCHECKBOX  Obtain from outside supplier/vendor. Source:  FORMTEXT        FORMCHECKBOX  No IMPORTANT: All production of lentiviral vector stocks will be conducted at BL2 using BL3 practices. All in-vitro work with lentiviral vector that is not tested for replication competent viral contaminants will be conducted at BL2 with BL3 practices. Lentiviral vector tested and proven to be free of replication competent viral contaminants may be handled at BL2. Consult the IU Vector Production Facility or the IBC for lentiviral testing information. List the assay that will be used to test lentiviral vector stocks for replication competent viral contaminants (if applicable):  FORMTEXT       Check ALL boxes applicable to your work using the lentiviral vector. Appropriate Biosafety levels are listed in parentheses. Tested means that the vector does not contain replication competent virus.  FORMCHECKBOX  Cell culture work  FORMCHECKBOX  Tested (BL2)  FORMCHECKBOX  Untested (BL2 with BL3 practices)  FORMCHECKBOX  Implantation of lentivirus-transduced cells in animals (BL2)  FORMCHECKBOX  Infection of animals with lentivirus vector (BL2)  FORMCHECKBOX  Tissue harvest from animals infected with lentivirus or implanted with lentivirus- transduced cells (BL2)  FORMCHECKBOX  Transgenic rodent made using lentivirus and then subsequent infection with another lentiviral system (BL2 with BL3 practices)  FORMCHECKBOX  Human clinical trial (BL2 with BL3 practices) 6. Does the vector expand the hosts range (is the product now potentially infectious in other organisms or cells not normally infected)?  FORMCHECKBOX  Yes, describe  FORMTEXT        FORMCHECKBOX  No 7. Does this project involve large scale (>10 liters of culture) research or production?  FORMCHECKBOX  Yes, additional guidelines apply. Contact the Biosafety Officer at 274-2830.  FORMCHECKBOX  No SECTION VII. CELL LINES AND PHYSICAL CONTAINMENT 1. Please list all microorganisms/whole animals/plants/cell lines/infectious agents that will be used as a host for the vectors described in questions 5 and 6: Refer to the most recent NIH guidelines  HYPERLINK "http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html" http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html Or CDC guidelines  HYPERLINK "http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4/toc.htm" http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4/toc.htm Or ABSA Risk Groups  HYPERLINK "http://www.absa.org/resriskgroup.html" http://www.absa.org/resriskgroup.html Infectious Agent/(Micro)Organism/Whole Animal/Cell line/Etc. NOTE: Work with human cell lines is considered RG2/BL2Source/VendorRisk Group (RG1, RG2, RG3, RG4)Biosafety Level (BL1/BL2/ BL2w/BL3 practices/BL3) FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       2. Please check the appropriate physical containment for this protocol. Refer to the most recent NIH guidelines  HYPERLINK "http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html" http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html Or CDC guidelines  HYPERLINK "http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4/toc.htm" http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4/toc.htm Or ABSA Risk Groups  HYPERLINK "http://www.absa.org/resriskgroup.html" http://www.absa.org/resriskgroup.html  FORMCHECKBOX  BL1  FORMCHECKBOX  BL2  FORMCHECKBOX  BL2 w/BL3 practices  FORMCHECKBOX  BL3 SECTION VIII. ABBREVIATIONS Include a list of abbreviations (with definitions) that are used in this study application. AbbreviationDefinition FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       SECTION IX. BIOSAFETY LEVELS Biosafety Level 1 or higher: The following guidelines apply to all biological research, regardless of the designated Biosafety Level at Loyola University Chicago. Handwashing: Hands must be washed immediately or as soon as feasible after removing gloves or other personal protective clothing. Personal Protective Equipment (PPE): PPE such as gloves, safety glasses and a laboratory coat should be worn whenever biological work is conducted in the laboratory. No sandals are allowed in the laboratory. Use of Sharps: Minimize the use of and exposure to sharps in the workplace. Never recap, bend or shear needles. As often as possible, replace glassware with less damaging materials such as plastic. Keep sharps containers readily available in all locations where sharps waste may be generated. In order to avoid accidental injury, do not overfill sharps containers. Food and Beverage: Eating, drinking, storing food and drink for human consumption, smoking, applying cosmetics or lip balm and handling contact lenses in the laboratory or other work areas is prohibited. This prohibition shall be well posted. Aerosol Generation: Any procedures that could potentially generate aerosols or other inhalation hazards must be performed in a manner that will minimize airborne pathogen transmission. Proper Labeling: Place a color-coded label incorporating the universal biohazard symbol on any potentially contaminated equipment or work surface to warn others of biohazard contamination that may not be easily visible. This includes freezers, refrigerators and incubators. Autoclave Safety: Always wear heat-resistant gloves, goggles or safety glasses, and a laboratory coat when opening an autoclave. Be sure to allow the superheated steam to exit before attempting to remove the contents. Spills: Always clean spills from the periphery of the spill towards the center, after placing paper towels over the spill. Make sure that the cleaning materials are disposed of in an appropriate manner. Mouth Pipetting: Mouth pipetting may lead to accidental ingestion of biological specimens and is strictly prohibited. Decontamination Procedures: A fresh 0.5 1 percent sodium hypochlorite (a 1 to 10-20 dilution of household bleach) will be used to decontaminate equipment and work surfaces. In locations where bleach would cause corrosion, an iodophor (e.g., Wescodyne) will be used to decontaminate. Local Transport of Infectious Materials: All infectious materials transported to and from the laboratory will be enclosed in a primary container with a sealed lid or top, which will then be enclosed in a secondary leak-proof, rigid container (e.g., a Coleman cooler) appropriately labeled with biohazard symbol. A responsible lab employee shall escort any specimens transported to and from off-campus satellite facilities. Packaging and labeling must comply with the IATA dangerous goods or DOT hazardous materials regulations. Storage: All infectious materials to be stored will be clearly labeled with the universal biohazard symbol as will the storage space (e.g., freezers and refrigerators). Bloodborne Pathogens: All PIs using human blood or blood products, unfixed tissue, body fluids or organ or cell cultures of human origin will follow the procedures outlined in the IUPUI Bloodborne Pathogen Exposure Control Plan. Transport of Select Agents/Toxins: EH&S must be notified of all transfers or shipments off campus. Are there proposed deviations from these standard procedures?  FORMCHECKBOX  Yes, describe  FORMTEXT        FORMCHECKBOX  No Biosafety Level 2 or higher: The following statements apply to research at Biosafety Level 2 or higher and must be completed by the Principal Investigator. Check all that apply. Agent Hazard: Agent(s):  FORMTEXT       Pathway(s):  FORMCHECKBOX  skin contact  FORMCHECKBOX  eye contact  FORMCHECKBOX  inhalation  FORMCHECKBOX  ingestion  FORMCHECKBOX  injection  FORMCHECKBOX  N/A Dangers:  FORMTEXT       Laboratory Access:  FORMCHECKBOX  Limited to personnel directly involved with research and who have been trained on protocol  FORMCHECKBOX  Locked laboratories with limited public access  FORMCHECKBOX  Other  FORMTEXT       Personal Protective Equipment and Practices:  FORMCHECKBOX  Lab Coats  FORMCHECKBOX  Latex gloves  FORMCHECKBOX  Face shield  FORMCHECKBOX  Safety glasses  FORMCHECKBOX  Masks  FORMCHECKBOX  Biosafety cabinet  FORMCHECKBOX  Other  FORMTEXT       Surveillance for infections:  FORMCHECKBOX  Sero-testing  FORMCHECKBOX  Baseline serum sampling  FORMCHECKBOX  N/A  FORMCHECKBOX  Other  FORMTEXT       Describe program  FORMTEXT       Disinfection procedures: (Note: solutions from stock concentrations must be assigned an expiration date)  FORMCHECKBOX  10% bleach (<24 hours old)  FORMCHECKBOX  70% ethanol  FORMCHECKBOX  1% SDS  FORMCHECKBOX  Iodophor  FORMCHECKBOX  Cidex  FORMCHECKBOX Other  FORMTEXT       Disposal methods:  FORMCHECKBOX  Animals: animal carcasses will be disposed of by the LARC facility.  FORMCHECKBOX  Solid biohazardous waste: will be autoclaved prior to disposal  FORMCHECKBOX  Liquid biohazardous waste: will be treated with bleach prior to disposal  FORMCHECKBOX  Other  FORMTEXT       Oversight: Day-to-day supervision of laboratory operations and personnel in PI s absence Name/Campus address/phone:  FORMTEXT       Transportation of animals:  FORMCHECKBOX  Conducted in approved cages and only with animals directly involved with the research performed  FORMCHECKBOX  Other  FORMTEXT        FORMCHECKBOX  Not applicable Transportation of Biohazardous Materials:  FORMCHECKBOX  Labeled, rigid, leakproof containers  FORMCHECKBOX  Other  FORMTEXT        FORMCHECKBOX  Not applicable In case of emergency, call: Name/number:  FORMTEXT       Aerosol containment:  FORMCHECKBOX  Vortexing/mixing/centrifugation performed in tightly capped tubes  FORMCHECKBOX  Centrifugation performed in aerosol containment capsules for BL3 containment  FORMCHECKBOX  Pipetting or other procedures performed in Biosafety cabinet  FORMCHECKBOX  Other  FORMTEXT        FORMCHECKBOX  Not applicable Health Surveillance/Immunization Programs If you are working with any of the agents listed below, you must develop an appropriate health surveillance and/or immunization program for the safe conduct of your protocol. If you need assistance, please contact the Biosafety Officer at ext. 83367. The following health surveillance immunization programs/requirements will be implemented: Bloodborne Pathogens: This training must be offered when human cell lines or human infectious agents are employed. HBV vaccination and declination form, post-exposure follow-up, treatment at no cost to employees, initial BBP training and annual  FORMCHECKBOX  Yes  FORMCHECKBOX  N/A retraining and universal precautions. Orthopoxviruses (vaccinia and others): Medical screening, vaccination and  FORMCHECKBOX  Yes  FORMCHECKBOX  N/A contraindication awareness and training Serum sample banking: Consult with Environmental Health and Safety  FORMCHECKBOX  Yes  FORMCHECKBOX  N/A If a custom health surveillance/immunization program will be in effect, please attach a one-paragraph description of this program. Be sure to consult Employee Health Services first. SECTION X. INVESTIGATOR STATEMENT The Principal Investigator is responsible for providing adequate training and supervision of staff in microbiological techniques and practices required to ensure safety and for procedures in dealing with accidents. The investigator is responsible for enforcing federal regulations regarding laboratory safety for all persons who work under his/her direct&? 0 ɷsaUL>66hFCJaJhphF5>*CJaJhF>*CJaJhyehF>*CJaJ#h:/#hF5>*B*CJaJphhdrFhF5>*CJaJhF5>*CJaJhyehF5>*CJaJhyehFCJaJ#hyehF6CJOJQJ^JaJ#hyehF5CJOJQJ^JaJ hyehFCJOJQJ^JaJ.jhFCJOJQJU^JaJmHnHuhFCJOJQJ^JaJ&?  K L &$d%d&d'dNOPQgdF-$ $d%d&d'dNOPQa$gdF gdF $ a$gdF /}0 @ B K M T W X Y ^ f r    & ' ( * : b e   - |tZRh!CJaJ2jxh:/#hF5>*B*CJUaJphhVBCJaJhphF5>*CJaJhF5>*CJaJ2jhhF5>*B*CJUaJph#h:/#hF5>*B*CJaJph,jh:/#hF5>*B*CJUaJphhdrFhF5CJaJhF5CJaJhyehFCJaJhFCJaJ - 1 4 5 J K L r $ & ( < > @ J L n v x 𨺖r`#jLhnFhFCJUaJ#jhnFhFCJUaJ#jdhnFhFCJUaJ"jhFCJUaJmHnHu#jhnFhFCJUaJjhFCJUaJhyehF5CJaJhyehFCJaJhThFCJaJhHCJaJhFCJaJhVBCJaJ%L r s N P B D LN|||||||* $d%d&d'dNOPQgdF* $d%d&d'dNOPQgdF* \$d%d&d'dNOPQgdF    0 2 4 > @ d h j ~  $&:Ͻϫϙχu#jhnFhFCJUaJ#jhnFhFCJUaJ#jhnFhFCJUaJ#j4hnFhFCJUaJ#jhnFhFCJUaJhFCJaJhyehFCJaJjhFCJUaJ"jhFCJUaJmHnHu.:<>:<><FtvļἪļĉļweļ#jhnFhFCJUaJ#jdhyehFCJUaJ#jhyehFCJUaJjhyehFCJUaJ#jzhnFhFCJUaJhFCJaJhyehFCJaJ"jhFCJUaJmHnHujhFCJUaJ#jhnFhFCJUaJ$ fh,4||||&$d%d&d'dNOPQgdFgdF, @ @$d%d&d'dNOPQgdF* $d%d&d'dNOPQgdF>@TVXbdļἪἘἆtp_ jhyehF5CJUaJhF#j* h0bhFCJUaJ#jh0bhFCJUaJ#j<hg hFCJUaJ#jhnFhFCJUaJhFCJaJhyehFCJaJ"jhFCJUaJmHnHujhFCJUaJ#jNhnFhFCJUaJ NPRfhjtvx,268Tûûïp\ûï&j hyehF5CJUaJ#j h!~hFCJUaJ5jhFCJOJPJQJU^JaJmHnHo(u#j hU )hFCJUaJjhFCJUaJhFCJaJhyehFCJaJ jhyehF5CJUaJ&j hyehF5CJUaJhyehF5CJaJ TVX*,.8:>@\^`ټُ}kYUhF"jhFCJUaJmHnHu#jd h3-hFCJUaJ#j h3-hFCJUaJ#jf hU )hFCJUaJ5jhFCJOJPJQJU^JaJmHnHo(u#j hU )hFCJUaJhyehFCJaJhFCJaJjhFCJUaJ#jx h3-hFCJUaJ!4<>*$%&'&$%&'$&:<>HJTо۩ССЖ{nZ{C{n,jh7hFCJOJQJUmHnHu'jPh7hFCJOJQJUh7hFCJOJQJ!jh7hFCJOJQJUh chF5CJhyehFCJaJhFCJaJ(jh7hFCJUaJmHnHu#j h7hFCJUaJh7hFCJaJjh7hFCJUaJhF5CJaJhyehF5CJaJ$LNPRTVXZ\^`FHJLNPRTVX&$d%d&d'dNOPQgdFgdFTX\^` 468BDXZ`dfz|ʼʨʉ}qhqWqCWq&j<hyehF5CJUaJ jhyehF5CJUaJhVB5CJaJhyehF5CJaJhFhFCJaJh7hF5CJaJ%jhF5CJUaJmHnHu&jh7hF5CJUaJjhF5CJUaJhF5CJaJhyehFCJaJh7hFCJaJh7hFCJOJQJhFCJOJQJXZ\^`bdj(*dh*$d%d&d'dNOPQ`gdFgdF&$d%d&d'dNOPQgdF$&*,HJL<>RTV`bo]#jh!~hFCJUaJ#jh!~hFCJUaJ#jh!~hFCJUaJ#j(hyehFCJUaJjhyehFCJUaJ5jhFCJOJPJQJU^JaJmHnHo(u#jh!~hFCJUaJhFCJaJjhFCJUaJhyehFCJaJ$FLOf󳤳~u~i뤳W~#jhyehFCJUaJhWhF5CJaJh!5CJaJhF5CJaJhhFCJaJ#jvhyehFCJUaJjhyehFCJUaJhyehFCJaJ5jhFCJOJPJQJU^JaJmHnHo(u#jh!~hFCJUaJhFCJaJjhFCJUaJhdfY* h$d%d&d'dNOPQgdF&$d%d&d'dNOPQgdF($d%d&d'dNOPQgdF*$d%d&d'dNOPQ`gdFfguvwy6TUcdegS T U ] ^ ! !!!.!C!I!Q!Z!j!s!t!!!!!!餙{oohhF5CJaJhQ%5CJaJhMThF5CJaJhVB5CJaJhyehFCJaJhchF5CJaJh!5CJaJ&jhchF5CJUaJhFCJaJ&jbha hF5CJUaJhF5CJaJjhF5CJUaJ+fSTT U !!.!B!I![!j! $IfgdF $$Ifa$gdF&$d%d&d'dNOPQgdFgdF2 hh$d%d&d'dNOPQ^h`gdFj!!!!!!!!!!!!!!!"."@"T"V"~"""""FfC$ $Ifa$gdF $IfgdFFf $$Ifa$gdF!!!!!!!",">"H"J"R"T"V"X"l"n"p"z"|"~""""""""""""""ĻĔċĻkĔĻWĔ&jhho,5CJUaJ&jxhho,5CJUaJhchF5CJaJhF5CJaJ%jh5CJUaJmHnHu&jhho,5CJUaJh5CJaJjh5CJUaJh2hF5CJaJh4hFCJH*aJhF5CJaJhMThF5CJaJ""""""""""""##### #"#6#8#:#D#F#H#J#^#`#b#l#n#p#r#########ݢݎzf&j<hho,5CJUaJ&jhho,5CJUaJ&jPhho,5CJUaJ&jhho,5CJUaJ%jh5CJUaJmHnHu&jdhho,5CJUaJh5CJaJhchF5CJaJjh5CJUaJ'" #H#p####$$:$<$>$f$$$$%.%V%~%%%%%%%$&Ff+Fft" 4$Ifgd $IfgdF###############$$ $$$$$($*$,$6$8$:$>$@$T$V$X$޿޶޿޶ރ޶of޶R&j%hho,5CJUaJhF5CJaJ&j,%hho,5CJUaJhchFCJaJ&j hho,5CJUaJ&j( hho,5CJUaJh5CJaJhchF5CJaJ%jh5CJUaJmHnHujh5CJUaJ&jhho,5CJUaJ X$b$d$f$h$|$~$$$$$$$$$$$$$$$$$$$$$$$%%%%%% %*%,%.%0%ɵɡɍye&j'hho,5CJUaJ&j'hho,5CJUaJ&j 'hho,5CJUaJ&j&hho,5CJUaJ&j&hho,5CJUaJh5CJaJhchF5CJaJjh5CJUaJ%jh5CJUaJmHnHu'0%D%F%H%R%T%V%X%l%n%p%z%|%~%%%%%%%%%%%%%%%%%%%%%%%%ԵԵԵyԵe\hF5CJaJ&jl.hho,5CJUaJ&j)hho,5CJUaJ&jd)hho,5CJUaJ&j(hho,5CJUaJhchF5CJaJ%jh5CJUaJmHnHujh5CJUaJ&jt(hho,5CJUaJh5CJaJ$%&&& &"&$&&&:&<&>&&&&&&&&&&&&&&&&&&&&&&&&&&&ԵԵԵԵԵ&0o,5C&᳢0o,5C&/o,5C&/o,5Cc5C%5CԱ5C&.o,5C5C$$&&&&&&'<'d'''''(.(V(~(((()F)H)J)r,t,0-gdFFf8>Ff4 $IfgdF&&&&&&&'''''''*','.'8':'<'>''''''''''''''''޿޶޿޶޿޶z޿޶޿޶&3o,5C&2o,5C&,2o,5C&1o,5C5Cc5C%5CԱ5C&<1hho,5CJUaJ#'''''''''''''''''(((((( (*(,(.(0(D(F(H(R(T(V(X(l(޹ޙ޹ޙ޹qޙ޹]ޙ޹&j9hho,5CJUaJ&j9hho,5CJUaJ&j8hho,5CJUaJhchF5CJaJ&j$8hho,5CJUaJh5CJaJhF5CJaJ%jh5CJUaJmHnHujh5CJUaJ&j7hho,5CJUaJ#l(n(p(z(|(~((((((((((((((((((((((( )))))) )4)޿޶޿޶޿޶z޿޶f޿޶&j;hho,5CJUaJ&jl;hho,5CJUaJ&j:hho,5CJUaJ&j|:hho,5CJUaJh5CJaJhchF5CJaJ%jh5CJUaJmHnHujh5CJUaJ&j:hho,5CJUaJ#4)6)8)B)D)H)+++++++J,L,`,b,d,n,p,r,-޿eQeChOhF5>*CJaJ&jjAhhF5CJUaJ>jhhF5CJOJPJQJU^JaJmHnHo(u&j@hhF5CJUaJhhF5CJaJ jhhF5CJUaJhF5CJaJhchF5CJaJ%jh5CJUaJmHnHujh5CJUaJ&j\<hho,5CJUaJ- -- -"-,-.-.... .*.,.2.4...//////////00(0)0*0r0s00p\&jCh5hF5CJUaJ&jBCh5hF5CJUaJ&jBhhF5CJUaJh4hFCJH*aJ&jVBhhF5CJUaJ8jhF5CJOJPJQJU^JaJmHnHo(u&jAhhF5CJUaJhF5CJaJjhF5CJUaJ#0-2-0.2.///0p00000.$d%d&d'dNOPQ^`gdF ^`gdF&$d%d&d'dNOPQgdFgdF 00000000000111,1-1.1/1]1p1r1s1111111ոճբwow`wN`wow#jEhv-hFCJUaJjhv-hFCJUaJhFCJaJhv-hFCJaJ&j"Ehv-hF5CJUaJhv-hF5CJaJ jhv-hF5CJUaJ hF5h!5CJaJ&jDh=>#hF5CJUaJhF5CJaJjhF5CJUaJ&j2Dh=>#hF5CJUaJ0111111111111 & F !$IfgdF$ & F !$Ifa$gdF&$d%d&d'dNOPQgdFgdF&$d%d&d'dNOPQgdF 1111111111122222#2$2223242ۮۖۂhS6h8jJHhv-hFB*CJOJQJU^JaJph)hv-hFB*CJOJQJ^JaJph2jhv-hFB*CJOJQJU^JaJph&hv-hF6CJOJQJ]^JaJ/j0Ghv-hFCJOJQJU^JaJ/jFhv-hFCJOJQJU^JaJ)jhv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ&hv-hF5CJOJQJ\^JaJ11112"2xdWGW$ & F$Ifa$gdF & F$IfgdF$ & F !$Ifa$gdFkdF$$Ifl4rL+h,Z4 laf4"2#252^2p22{n^Q  & F$IfgdF$ & F$Ifa$gdF & F$IfgdF$ & F$Ifa$gdFskdG$$Ifl4\L+h,Z4 laf44252^2_2m2n2o2p2222222222222233 3٬٘ـfIf5hP/j6Rhv-hFCJOJQJU^JaJ/jQhv-hFCJOJQJU^JaJ/jPhv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ/jOhv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ)jhv-hFCJOJQJU^JaJ/jOhv-hFCJOJQJU^JaJ444x444{n^L & F d$IfgdF$ & F$Ifa$gdF & F$IfgdF$ & F$Ifa$gdFskdP$$Ifl4\L+h,Z4 laf444444 5 5D5P5t55wwjZjjjjj$ & F$Ifa$gdF & F$IfgdF$ & F !$Ifa$gdFskdQ$$Ifl4\L+h:,4 laf4 >5@5B5P5R5n5p5r5555555555596:6H6I6J6R6S6a6b6c66yaI/jDYhv-hFCJOJQJU^JaJ/j*Xhv-hFCJOJQJU^JaJ/jThv-hFCJOJQJU^JaJ/jShv-hFCJOJQJU^JaJ/j"Shv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ)jhv-hFCJOJQJU^JaJ/jRhv-hFCJOJQJU^JaJ555556696K6Q6 & F d$IfgdF$ & F !$Ifa$gdFFfU & F !$IfgdF$ & F$Ifa$gdF & F$IfgdF Q6R6d666666wfffR@ & F d$IfgdF$ & F !$Ifa$gdF & F !$IfgdF$ & F !$Ifa$gdFskdX$$Ifl4\L+h:,4 laf466666666666666667777)7*78797:7G7H7V7W7٩ّyaI/j]hv-hFCJOJQJU^JaJ/jb\hv-hFCJOJQJU^JaJ/j[hv-hFCJOJQJU^JaJ/jv[hv-hFCJOJQJU^JaJ/j0Zhv-hFCJOJQJU^JaJ/jYhv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ)jhv-hFCJOJQJU^JaJ66667)7eQDDD & F$IfgdF$ & F !$Ifa$gdFkdZ$$Ifl4ֈL +  ,Z4 laf4)7;7F7G7Y7?+$ & F !$Ifa$gdFkd\$$Ifl4ֈL\ +@ ~ ,Z4 laf4 & F d$IfgdF$ & F !$Ifa$gdFW7X7p7q777777777777888&8'858687888j8٧u]٧@8j`hv-hFB*CJOJQJU^JaJph/j_hv-hFCJOJQJU^JaJ8j*_hv-hFB*CJOJQJU^JaJph)hv-hFB*CJOJQJ^JaJph2jhv-hFB*CJOJQJU^JaJph/j^hv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ)jhv-hFCJOJQJU^JaJY7p777777TD7 & F$IfgdF$ & F$Ifa$gdFskd^$$Ifl4\L+,Z4 laf4 & F d$IfgdF$ & F !$Ifa$gdF & F !$IfgdF7 8%8&888j8|88iYL & F$IfgdF$ & F$Ifa$gdFskd`$$Ifl4\L+h,Z4 laf4 & F d$IfgdF$ & F$Ifa$gdFj8k8y8z8{888888888888888888٭ٓ~a~٭Iٓ~/jbhv-hFCJOJQJU^JaJ8jJbhv-hFB*CJOJQJU^JaJph)hv-hFB*CJOJQJ^JaJph2jhv-hFB*CJOJQJU^JaJph&hv-hF5CJOJQJ\^JaJ/j0ahv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ)jhv-hFCJOJQJU^JaJ888888{n^L & F d$IfgdF$ & F$Ifa$gdF & F$IfgdF$ & F$Ifa$gdFskda$$Ifl4\L+h,Z4 laf4888.9/9{]I$ & F !$Ifa$gdF & F hp@ P !$`'$IfgdF$ & F$Ifa$gdFskd6c$$Ifl4\L+h,Z4 laf48888.999:9H9I9J9K9v9w9999999ɴɴrɴ]E]1&hv-hF6CJOJQJ]^JaJ/jjehv-hFCJOJQJU^JaJ)jhv-hFCJOJQJU^JaJ8jdhv-hFB*CJOJQJU^JaJph hv-hFCJOJQJ^JaJ&hv-hF5CJOJQJ\^JaJ)hv-hFB*CJOJQJ^JaJph2jhv-hFB*CJOJQJU^JaJph8jchv-hFB*CJOJQJU^JaJph/98999K9v99l\O?$ & F$Ifa$gdF & F$IfgdF$ & F$Ifa$gdFskdPd$$Ifl4\L+h,Z4 laf4 & F !hp@ P !$`'d$IfgdF9999999zj]I]$ & F !$Ifa$gdF & F$IfgdF$ & F$Ifa$gdFskde$$Ifl4\L+h,Z4 laf4 & F !$IfgdF9999999999999: : : :,:5:6:D:E:F:G:٬٘s٘Y<Z<[<m<ZJ88J & F d$IfgdF$ & F$Ifa$gdFkdp$$Ifl4rL +h@ ` ,Z4 laf4 & F hp@ P !$`'$IfgdF;<<<=<[<\<j<k<l<m<<<<<<<<<<<<<<<<<<<<<==}eM/jthv-hFCJOJQJU^JaJ/jhshv-hFCJOJQJU^JaJ/jrhv-hFCJOJQJU^JaJ&hv-hF6CJOJQJ]^JaJ/jqhv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ)jhv-hFCJOJQJU^JaJ/jGqhv-hFCJOJQJU^JaJm<<<<<<<k[II5$ & F !$Ifa$gdF & F d$IfgdF$ & F$Ifa$gdFkd3r$$Ifl4rL +h@  ,Z4 laf4 & F$IfgdF<<<<==!=k[II5$ & F !$Ifa$gdF & F d$IfgdF$ & F$Ifa$gdFkds$$Ifl4rL +h@  ,Z4 laf4 & F$IfgdF=== =!=B=C=D=R=S=T=e=f=t=u=v=w==========~hP/jwhv-hFCJOJQJU^JaJ*hv-hF0J6CJOJQJ]^JaJ/jvhv-hFCJOJQJU^JaJ/jHvhv-hFCJOJQJU^JaJ&hv-hF6CJOJQJ]^JaJ)jhv-hFCJOJQJU^JaJ/juhv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ!=B=C=U=d=e=w=k[II5$ & F !$Ifa$gdF & F d$IfgdF$ & F$Ifa$gdFkdu$$Ifl4rL +h@  ,Z4 laf4 & F$IfgdFw======gWEE & F d$IfgdF$ & F$Ifa$gdFkd4w$$Ifl4rL +h@  ,Z4 laf4 & F !$IfgdF========>>>> >!>7>J>K>Y>Z>[>}>~>>>>>>>>>>}eM}}/j{hv-hFCJOJQJU^JaJ/jD{hv-hFCJOJQJU^JaJ&hv-hF6CJOJQJ]^JaJ/jzhv-hFCJOJQJU^JaJ/jyhv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ)jhv-hFCJOJQJU^JaJ/jixhv-hFCJOJQJU^JaJ=====>SC1 & F d$IfgdF$ & F$Ifa$gdFkdx$$Ifl4rL +h@  ,Z4 laf4 & F !$IfgdF$ & F !$Ifa$gdF>>!>I>J>\>A1$ & F$Ifa$gdFkdz$$Ifl4rL +h@  ,Z4 laf4 & F !$IfgdF$ & F !$Ifa$gdF & F d$IfgdF\>|>}>>>>Akd0|$$Ifl4rL +h@  ,Z4 laf4 & F !$IfgdF$ & F !$Ifa$gdF & F d$IfgdF>>>>>>>>>>>>> ???6?7?E?F?G?H?[?\?]?k?l?m????~fN/j hv-hFCJOJQJU^JaJ/j~hv-hFCJOJQJU^JaJ/jz~hv-hFCJOJQJU^JaJ&hv-hF6CJOJQJ]^JaJ/j`}hv-hFCJOJQJU^JaJ)jhv-hFCJOJQJU^JaJ/j|hv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ>>>>>>?6?Xskd}$$Ifl4\L+h,Z4 laf4 & F !$IfgdF & F d$IfgdF$ & F$Ifa$gdF6?H?[?\?n????fVD & F d$IfgdF$ & F$Ifa$gdFskdf$$Ifl4\L+h,Z4 laf4 & F !$IfgdF$ & F !$Ifa$gdF??????????@@@@@2@3@A@B@C@T@@@|dL:#h~(hF5CJOJQJ^JaJ/jVhv-hFCJOJQJU^JaJ/jhv-hFCJOJQJU^JaJ/jhv-hFCJOJQJU^JaJ(hv-hFCJOJQJ^JaJmHsH.hv-hF6CJOJQJ]^JaJmHsH hv-hFCJOJQJ^JaJ)jhv-hFCJOJQJU^JaJ/jhv-hFCJOJQJU^JaJ????@@@@@@@{iXXXXXXX & F !$IfgdF & F d$IfgdF$ & F$Ifa$gdFskd$$Ifl4\L+h,Z4 laf4 @@@,$ & F$Ifa$gdFkd$$Ifl4 Lk"%(+h,Z$$$$4 laf4@*@+@,@-@.@/@0@1@ & F !$IfgdF & F d$IfgdF1@2@D@,$ & F$Ifa$gdFkdn$$Ifl4 Lk"%(+h,Z$$$$4 laf4D@T@@@@AAyi$ & F$Ifa$gdFbkd̄$$Ifl4FL+h`,Z    4 laf4 & F !$IfgdF & F d$IfgdF@@@@@@AA+A,A-A[A\AjAkAlAmAAAAAAAѴѣv^JJ&hv-hF6CJOJQJ]^JaJ/jyhv-hFCJOJQJU^JaJ/jlhv-hFCJOJQJU^JaJ)jhv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ8jchv-hFB*CJOJQJU^JaJph)hv-hFB*CJOJQJ^JaJph2jhv-hFB*CJOJQJU^JaJphAA.AYAZA|k & F !$IfgdF & F d$IfgdF$ & F$Ifa$gdF`kdم$$Ifl4FL+h ,Z    4 laf4ZA[AmAAAzi & F !$IfgdF & F d$IfgdF$ & F$Ifa$gdFbkd$$Ifl4IFL+h ,Z    4 laf4AAAAAzi & F !$IfgdF & F d$IfgdF$ & F$Ifa$gdFbkd$$Ifl4IFL+h ,Z    4 laf4AAAAAAAAAABB B!B/B0B1B2BCBMBNBɴzbzNz6zz/j9hv-hFCJOJQJU^JaJ&hv-hF5CJOJQJ\^JaJ/jhv-hFCJOJQJU^JaJ)jhv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ&hv-hF6CJOJQJ]^JaJ)hv-hFB*CJOJQJ^JaJph2jhv-hFB*CJOJQJU^JaJph8jhv-hFB*CJOJQJU^JaJphAAABB|k & F !$IfgdF & F d$IfgdF$ & F$Ifa$gdF`kd$$Ifl4FL+h ,Z    4 laf4BBBBB{{ & F !$IfgdF$ & F$Ifa$gdFbkd$$Ifl4FL+h ,Z    4 laf4B B2BKBLBww & F !$IfgdF$ & F !$Ifa$gdFbkd$$Ifl4FL+h ,Z    4 laf4LBMB_B|B}B{j & F !$IfgdF & F$IfgdF$ & F !$Ifa$gdFbkd$$Ifl4FL+h ,Z    4 laf4NB\B]B^B_BuB{B|B~BBBBBBBBBBBBBBBBCC"Cvk_k_V_V_E_ jhyehF5CJUaJhF5CJaJhyehF5CJaJhyehFCJaJhv-hF5CJaJ/jShv-hFCJOJQJU^JaJ&hv-hF5CJOJQJ\^JaJ&hv-hF6CJOJQJ]^JaJ)jhv-hFCJOJQJU^JaJ/jFhv-hFCJOJQJU^JaJ hv-hFCJOJQJ^JaJ}B~BBBBve & F !$IfgdF & F d$IfgdF$ & F !$Ifa$gdFbkd$$Ifl4FL+h ,Z    4 laf4BBBBBBCDD\E^EfaaffffagdF&$d%d&d'dNOPQgdFP^`PgdFbkdɍ$$Ifl4dFL+h ,Z    4 laf4 "C#C$C&C/C0C:C;CD D DDDH@HBHDHXHZH\HfHhHjHlHHHHHHHHHt#jhho,CJUaJ#j{hho,CJUaJ#jhho,CJUaJ#jhho,CJUaJ"jhCJUaJmHnHu#jhho,CJUaJhCJaJh`[hFCJaJjhCJUaJ'GGHHBHjHH^UUUUU $IfgdFkd$$Ifl\ Y|)` y# t0644 laHHHHHI6I^UUUUU $IfgdFkdk$$Ifl\ Y|)` y# t0644 laHHHHHHHHHHHHHHHHI I III$I&I(I2I4I8I:I@IBInJJKK0KἪἘἆzrizizXz jhyehF5CJUaJhF5CJaJhFCJaJhyehF5CJaJ#j^hho,CJUaJ#jhho,CJUaJ#jnhho,CJUaJhCJaJh`[hFCJaJ"jhCJUaJmHnHujhCJUaJ#jhho,CJUaJ"6I8II@IK^YYY2&$d%d&d'dNOPQgdFgdFkd֚$$Ifl\ Y|)` y# t0644 la0K2K4K8KTKVKjKlKnKxKzKKKKKKKKL L&L MMM,M.M0M4MPMRMfMĸ}k}bbbNĸ&jÜhyehF5CJUaJhF5CJaJ#jMhyehFCJUaJjhyehFCJUaJ"jhFCJUaJmHnHu#jכhphFCJUaJhFCJaJjhFCJUaJhyehFCJaJhyehF5CJaJ jhyehF5CJUaJ&jahyehF5CJUaJK|K~KKK MxMzMMMMOO|O~OOO. $d%d&d'dNOPQ^ `gdFgdF&$d%d&d'dNOPQgdFfMhMjMtMvM|M~MMMMMMMOO0O2O4O8OTOVOjOlOnOxOzOOOOĵģĞxdx\Jĵ#jhxhFCJUaJhFCJaJ&j%hyehF5CJUaJ jhyehF5CJUaJhyehF5CJaJhF5CJaJ hF5#jhyehFCJUaJjhyehFCJUaJhyehFCJaJ"jhFCJUaJmHnHujhFCJUaJ#j9hxhFCJUaJOOOOOOOOrPtPPPPPPPPPPPPPPQQQQQQ¶ӅsaO¶#jshyehFCJUaJ"jhFCJUaJmHnHu#jhxhFCJUaJjhFCJUaJ&jhyehF5CJUaJ jhyehF5CJUaJhyehF5CJaJhF5CJaJhFCJaJhyehFCJaJjhyehFCJUaJ#jhyehFCJUaJOnPPPQQQ8RjRlR~* h$d%d&d'dNOPQgdF&$d%d&d'dNOPQgdF.h$d%d&d'dNOPQ^h`gdF Q6RRZR\R^RbRpRrRRRRRSSS2S4S6S@SBSHSSSS涧o]TFTh hF5CJH*aJhF5CJaJ"jhFCJUaJmHnHu#jաhxhFCJUaJjhFCJUaJhFCJaJ#j_hyehFCJUaJjhyehFCJUaJhyehFCJaJ&jhyehF5CJUaJ jhyehF5CJUaJhyehF5CJaJhyehF56CJaJlRDSFSSdTTTVBVhhhhh4 @@$d%d&d'dNOPQ^`gdF4 h@$d%d&d'dNOPQ^`gdF.$d%d&d'dNOPQ^`gdFSS T T TThTiTwTxTyTTTTTTTTTTTUU'U(UV V VVͯ͋͝|q_|J|q(jhxhFCJUaJmHnHu#j+hxhFCJUaJhxhFCJaJjhxhFCJUaJ#jhZswhFCJUaJ#j;hZswhFCJUaJ#jâhZswhFCJUaJjhFCJUaJhFCJaJ&jKhZswhF5CJUaJhF5CJaJjhF5CJUaJVVV2V4V6VDV\VWWXXXXXXXXXXXXXuYvYwYYYZ Z ZZZ[[[[[[\\\k&jhy7hF5CJUaJjhF5CJUaJhF>*CJaJ"jhFCJUaJmHnHu#jh 4hFCJUaJh7hFCJaJh7hF5CJaJhF5CJaJ#jh<hFCJUaJjhFCJUaJhFCJaJ)BVWWiXXXXWYZZ_4 @@$d%d&d'dNOPQ^`gdF5 @@$d%d&d'dNOPQ^`gdF5 @@$d%d&d'dNOPQ^`gdF ZZ[[W\\\[]v]v-  @@@$d%d&d'dNOPQgdF, @@$d%d&d'dNOPQgdF/ @@$d%d&d'dNOPQgdF\\\"\#\1\2\3\Z\[\i\j\k\\\\\\\\]]]y]z]]]]^^!^"^#^W^X^ٵ٣ّmbhZswhFCJaJ#jרhP,5hFCJUaJ#j_hP,5hFCJUaJ#jhy7hFCJUaJ#johy7hFCJUaJ#jhy7hFCJUaJ#jh`$hFCJUaJhFCJaJjhFCJUaJ#jh`$hFCJUaJ"v]]^X^^``>`@``aaaazzzuzzzzugdF&$d%d&d'dNOPQgdF. $d%d&d'dNOPQ^ `gdF/ p @@@@$d%d&d'dNOPQgdF X^Y^^^^^^^____` ` ```0`2`4`>`@`B```aaaaaa꺮sassOss#jhyehFCJUaJ#j;hyehFCJUaJjhyehFCJUaJ"jhFCJUaJmHnHu#jũhphFCJUaJhFCJaJjhFCJUaJhyehFCJaJ&jOhyehF5CJUaJ jhyehF5CJUaJhyehF5CJaJhF5CJaJaaaaa'b(b)b*bkb}bbbbbbbbb:c;cxGx y yyyyyzzz|||]}^}u}E~F~j~~~~~~~~ &jhCjhF5CJUaJ&jhT1"hF5CJUaJjhF5CJUaJhT1"hF5CJaJh.hF5CJaJhFCJaJhVB5CJaJhF5CJaJ6fpqZrII & FEƀz.gdFk & F$d%d&d'dEƀz.NOPQgdFZr,stuk!I & FEƀz.gdFI & FEƀz.gdFI & FEƀz.gdFuMvbw>xk!I & FEƀz.gdFI & FEƀz.gdFI & FEƀz.gdF>x yyzk!I & FEƀz .gdFI & FEƀz .gdFI & FEƀz.gdFz|^}F~k!I & FEƀz .gdFI & FEƀz .gdFI & FEƀz .gdFF~~~~~~:*8$d%d&d'dNOPQ^8gdF8^8gdFI & FEƀz.gdF ,.0<ā؁ځ68:Z\xz|յթq_M#jhT1"hFCJUaJ#jshT1"hFCJUaJ"jhFCJUaJmHnHu#jhCjhFCJUaJjhFCJUaJhFCJaJhT1"hF5CJaJhTxhF5CJaJ&jhT1"hF5CJUaJhF5CJaJjhF5CJUaJ%jhF5CJUaJmHnHu:ātI@@@@^gdFI & FEƀz.gdFk & F$d%d&d'dEƀz.NOPQgdFԂւ,.0HJfhjڃ܃ރքڀwe#jhhFCJUaJhF5CJaJ"jhFCJUaJmHnHu#j9hCjhFCJUaJ#jh:hFCJUaJ#jKhT1"hFCJUaJ#jhT1"hFCJUaJjhFCJUaJ#j_hT1"hFCJUaJhFCJaJ#܃<h‡bI & FEƀz.gdF^gdFI & FEƀz.gdF ք؄ڄ<>Z\^np,.JLNlnٵٚm[#jhhFCJUaJ&jhhF5CJUaJjhF5CJUaJhhFCJaJhF5CJaJ"jhFCJUaJmHnHu#jhCjhFCJUaJ#jhhFCJUaJhFCJaJjhFCJUaJ#j%hhFCJUaJȆʆ̆  ">@Bhj‡ٵ٣ّmdVdjhF5CJUaJhF5CJaJ"jhFCJUaJmHnHu#jhCjhFCJUaJ#jKhhFCJUaJ#jhhFCJUaJ#j_hhFCJUaJ#jhhFCJUaJhFCJaJjhFCJUaJ#jshhFCJUaJ!‡df:ȋʋbI & FEƀz.gdF^gdFI & FEƀz.gdF <>Z\^ˆĈ <>ՉՉډͯ͋͝ygͱg#䴳"䴳Ա#䴳#䴳#%,5䴳#䴳䴳䴳5C5C&75C!ډ:<XZ\^Ԋ֊ &(*@B^`brt̮̜̊xf#jYhihFCJUaJ#jhihFCJUaJ#jihihFCJUaJ#jhihFCJUaJ#jyhihFCJUaJjhFCJUaJhFCJaJ&jhihF5CJUaJjhF5CJUaJhF5CJaJ"ċƋʋOP^_`#$ ĎǾǬǚLjvdǾ#j'hCjhFCJUaJ#jhmhFCJUaJ#j7hmhFCJUaJ#jhmhFCJUaJ#jGhihFCJUaJhF5CJaJhFCJaJ"jhFCJUaJmHnHujhFCJUaJ#jhCjhFCJUaJ%ʋOĎ"$bI & FEƀz.gdF^gdFI & FEƀz.gdF  $Z\xz|@B^`brt46RǾNJxfǾ#jyhhhFCJUaJ#jhCjhFCJUaJ#jh&\~hFCJUaJ&jh hF5CJUaJjhF5CJUaJhF5CJaJhFCJaJ"jhFCJUaJmHnHujhFCJUaJ#jhCjhFCJUaJ $Z@ސ4BDbI & FEƀz .gdF^gdFI & FEƀz.gdF RTV‘đƑ֑ؑ D|ٵن}k}]}jhF5CJUaJ#jhCjhFCJUaJhF5CJaJ#jWh&\~hFCJUaJhhhFCJaJ"jhFCJUaJmHnHu#jhCjhFCJUaJ#jih&\~hFCJUaJhFCJaJjhFCJUaJ#jhhhFCJUaJ D|TNb]gdFI & FEƀz .gdF^gdFI & FEƀz .gdF  TVrtv&(<>@JLNPlnpͯ͋͝ygU#jh&\~hFCJUaJ"jhFCJUaJmHnHu#j%h9hFCJUaJ#jh&\~hFCJUaJ#j5h&\~hFCJUaJ#jhTxhFCJUaJjhFCJUaJhFCJaJhF5CJaJjhF5CJUaJ&jEh&\~hF5CJUaJd—EFTUV[\jkl˜ <SĸĦĸĔĸĂĸpĸ^ĸ#jh^hFCJUaJ#j{h^hFCJUaJ#jh^hFCJUaJ#jhchFCJUaJ#jhchFCJUaJjhFCJUaJhFCJaJhF5;>*CJaJ&h'hF5;>*B*CJaJphhF5CJaJh&\~hFCJaJ$LM—q}l} X (#%^gdF ^gdF^gdFk & F$d%d&d'dEƀz.NOPQgdF ;<defghipppp4 T$ $d%d&d'dNOPQ^gdF T$ ^gdF T$ X (#%^gdF T ^gdF T X (#%@^gdF  ^gdF 5>[lms?  p!q!!!!!!!!!!!!!!"ǿǿǴǿǴٴǩǿǴzqzk hCJhOhF0JhOhF0JCJjhOhFCJUhFjhFCJU hXCJhJGhFCJaJh hFCJaJ hFCJUh hFCJhF5CJaJhFCJaJjhFCJUaJ#jkh^hFCJUaJ*ijklmnopqrstuvwgdF&$d%d&d'dNOPQgdF T$ gdF4 T$ $d%d&d'dNOPQ^gdFion. The investigator is responsible for correcting work errors and conditions that may result in the release of rDNA materials, biohazardous materials, or infectious agents and ensuring the integrity of the physical containment. Any work related injury or exposure must be reported to The Biosafety Officer. The investigator is also responsible for ensuring that co-investigators, if any, employ the necessary safeguards to protect laboratory personnel, students, and the community from potential hazards posed by the project. The investigator must ensure that staff has read this protocol and the Biosafety manual. I certify that I have read the above statements and agree that I and all listed participants will abide by those statements as well as all ݮ policies and procedures governing the use of infectious agents and other biological materials as outlined in this application and in the ݮ Biosafety Manual. In addition, I will: Abide by the General Duty Clause of OSHA and take full responsibility to ensure that listed personnel have received or will receive appropriate training in safe laboratory practices and procedures for this protocol before any work begins on this project and at least annually thereafter. Also, all listed personnel who have occupational exposure to bloodborne pathogens will be trained annually; Follow the health surveillance practices as approved for this protocol and inform those working on the protocol about appropriate emergency assistance information for their location(s); Inform Employee Health Services of any research-related accident or illness as soon as possible after its occurrence; Submit in writing a request for approval from RSP of any significant modifications to the study, facilities or procedures; and; Adhere to ݮ Biosafety guidelines referred to in this application as well as comply with the requirements of the Biosafety Manual. I understand my responsibility with regard to laboratory safety and certify that the protocol as approved by the IBC will be followed during the period covered by this research project. Any future changes will be submitted for IBC review and approval prior to implementation. Changes, such as adding co-investigators, cell lines, or transgenic animals may be submitted by downloading the amendment form from the Loyola Compliance website at  HYPERLINK "http://www.research.luc.edu/compliance" http://www.research.luc.edu/compliance and submitting itto the IBC. Major changes, such as adding new infectious agents or upgrading Biosafety levels may require additional documentation besides the completed amendment form. To ensure that the IBC has the most current information when reviewing a study, it has established a 3-year re-review policy for on-going IBC studies that have been approved at BL-1 or higher. The policy requires principal investigators (PIs) to submit a protocol renewal/update form to the IBC every 3 years. I understand I must submit the protocol renewal/update form in advance of the renewal date to the IBC. Signature of Investigator: Date:Signature of Authorized IBC Representative: Date:Signature of Biosafety Officer: Date: Appendix A Definitions from the NIH Guidelines for use of Exempt rDNA Molecules Recombinant DNA: In the context of the NIH guidelines, recombinant DNA molecules are defined as either: 1. Molecules that are constructed outside living cells by joining natural or synthetic DNA segments to DNA molecules that can replicate in a living cell, or 2. Molecules that result from the replication of those described in 1. Exempt Categories of rDNA Experiments (if any apply, Complete this registration): --NIH Guidelines (Section III-F; Appendix A, Appendix C) 1. rDNA containing less than 2/3 of an eukaryotic viral genome propagated in cell culture (with the exception of DNA from Risk Group 3, 4, or restricted agents) 2. rDNA work involving E. coli K12, S. cerevisiae, and B. subtilis hot-vector systems (with the exception of DNA from Risk Group 3, 4, or restricted agents). Exempt registrations are reviewed by an expedited process. 3. Those that are not in organisms or viruses. 4. Those that consist entirely of DNA segments from a single nonchromosomal or viral DNA source, though one or more of the segments may be a synthetic equivalent. 5. Those that consist entirely of DNA from a prokaryotic host including its indigenous plasmids or viruses when propagated only in that host (or a closely related strain of the same species), or when transferred to another host by well established physiological means. 6. Those that consist entirely of DNA from a eukaryotic host including its chloroplasts, mitochondria, or plasmids (but excluding viruses) when propagated only in that host (or a closely related strain of the same species). 7. Those that consist entirely of DNA segments from different species that exchange DNA by known physiological processes, though one or more of the segments may be a synthetic equivalent. A list of such exchangers can be found in  HYPERLINK "http://www4.od.nih.gov/oba/rac/guidelines_02/" \l "_Section_IV-C-1-b-(1)._Major" Section IV-C-1-b-(1)-(c), Major Actions). For a list of natural exchangers that are exempt from the NIH Guidelines, see  HYPERLINK "http://www4.od.nih.gov/oba/rac/guidelines_02/APPENDIX_A.htm" \n Appendices A-I through A-VI, Exemptions Under Section III-F-5--Sub lists of Natural Exchangers. Those that do not present a significant risk to health or the environment (see  HYPERLINK "http://www4.od.nih.gov/oba/rac/guidelines_02/" \l "_Section_IV-C-1-b-(1)._Major" Section IV-C-1-b-(1)-(c), Major Actions), as determined by the NIH Director, with the advice of the RAC, and following appropriate notice and opportunity for public comment. See  HYPERLINK "http://www4.od.nih.gov/oba/rac/guidelines_02/APPENDIX_C.htm" \n Appendix C, Exemptions under Section III-F-6 for other classes of experiments which are exempt from the NIH Guidelines. Appendix B Example of Completed Table for Question B.7 Nature/Source of DNAHost(s)Vector(s)Experimental UseMajor histocompatibility complex class II (mouse) E. coli (K-12) E. coli YeastPlasmid, Bluescript, pET21 pDHILCloning, sequencing Over-expression of protein in E. coli for structure/function Over expression of protein in yeast for structure/functioncDNA (human) for MAP kinaseE. coli Cultured mammalian cells (not human or primate cells) Lambda gt10 Commercially available plasmidsCDNA Library, screen for clonescDNA (human) for protein kinase A (wild-type and mutant forms of) cDNA (mouse) for nonmuscle myosin heavy chainCultured mammalian cells (not human or primate cells)pRC2 and pCMV2Over-expression of recombinant protein in cultured cells; functional studies Heme B3-8 gene (human)E. colipUC19PCR amplification to generate probe for screening cDNA and genomic libraryPromoter of BMP2 (mouse)E. coli F9 cells (mouse)Reporter plasmid, pGL2-promoter (luciferase)Transient transfections to study promoter activityNitric oxide synthase (bovine)E. coli Insect cells (SF9) Cultured cells (not human or primate), yeastPlasmid, pFASTBAC. Baculovirus, AcNPV, pCMV5Over- FORMDROPDOWN expression of protein or mutant forms of the protein in insect or mammalian cellsBeta-Galactosidase (LacZ gene), (E. coli); Green fluorescent protein (GFP)E. coliPlasmid, pUB110, pS194, pT127Gene expression and function studies  Appendix C Definition of Transgenic Animal This section covers experiments involving whole animals in which the animal's genome has been altered by stable introduction of recombinant DNA, or DNA derived therefrom, into the germ-line (transgenic animals) and experiments involving viable recombinant DNA-modified microorganisms tested on whole animals. For the latter, other than viruses which are only vertically transmitted, the experiments may not be conducted at BL1-N containment. A minimum containment of BL2 or BL2-N is required. Appendix D LAB PERSONNEL NameTitleResponsibilities FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT        FORMTEXT       FORMTEXT       FORMTEXT        FORMTEXT       FORMTEXT       Appendix E Loyola University Chicago Institutional Biosafety Committee Minimum Guidelines for TAT Protein Use The IBC has become aware of investigators either wanting to initiate or purchase Trans-Activating Transduction (TAT) proteins or other tags which promote protein entry into cells. Many investigators initially view TAT fusion protein expression vectors- as just one of the many plasmids, which they may use in their laboratory and as such, submission to the IBC may be a unexpected requirement. They may also view use of TAT fusion proteins outside the purview of the IBC. Expression of a TAT- fusion protein, even in bacteria, is considered rDNA work and falls under the auspice of the IBC particularly since the TAT protein has potentially distinctive and unknown infectious qualities. As such, the use of the TAT protein is categorized as biosafety level 2 (BSL2). TAT Protein use may be pursued if the guidelines listed below are followed: A. Laboratory Containment, Practice, and Technique for TAT (or similar) protein studies (BL2): TAT Protein must be handled as a potentially hazardous material. Some proteins are more toxic and/or immunogenic and should be identified. Plastic backed absorbent lab paper should be used on all laboratory bench surfaces to absorb spills and splashes. All things that come in contact with TAT proteins should be regarded as contaminated. Biological safety cabinet (preferred) or designated space is recommended. Avoid aerosol-generating activities or use appropriate safety equipment such as biological safety cabinets and sealed centrifuge tubes. B. Personal Protection required: Mouth pipetting is NOT allowed. Lab coats must be worn. Disposable latex, nitrile, or equivalent gloves must be used. Safety goggles must be worn. Avoid direct contact with the skin, cuts, mucous membranes. Wash well after working with TAT material. C. Decontamination Procedures: In the event of a spill, while wearing gloves, lab coat, and safety glasses: Decontaminate work surfaces using a detergent with a protease enzyme (like Terg-A-Zyme) for 10-20 minutes. Wash with water and then wipe with a 70% ethyl alcohol solution. D. Disposal Procedures: Deactivate and dispose of TAT solutions and cultures using standard autoclave procedures. Dilute solutions can be deactivated using a 1:10 dilution of bleach (sodium hypochlorite solution) in a 1:1 mixture with the TAT solution, let sit for five to ten minutes. Dispose by sewer drain with copious amounts of water. E. TAT Protein research approval: TAT Protein research must be approved by the IBC prior to its initiation. When any revision to an approved protocol is desired, an amendment must be filled with the IBC. The IBC reserves the right to approve exceptions to the above guidelines on a case-by-case basis. A protocol or an amendment to an existing protocol must be submitted to purchase, synthesize or express TAT proteins. The protocol or amendment must indicate: What peptide you are linking on to What you are using as target cells What are the harmful consequences, if any, when expressed? References: Becker-Hapak M, McAllister SS, Dowdy SF. TAT-mediated protein transduction into mammalian cells. Methods. 2001 Jul;24(3):247-56. Review. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. 2000 Jul;10(7):290-5. Review. Backus, B.D., Dowdy, S.F., Boschert, K.R., and Richards, T.L, Becker-Hapak, M. (2000). Safety Guidance for Laboratory Personnel Working with Trans-Activating Transduction (TAT) Protein Transduction Domains. American Chemical Society Journlmi#fI & FEƀzgdFI & FEƀzgdFgdF#kbh^hgdzZI & FEƀzgdFI & FEƀzgdF  "".$/$J$K$L$R$ $IfgdFgdFI & FEƀzgdF "?"M"""""#####*$/$$$$$$$$$$%&&&,񸧖kgZJZh"m9hF6OJQJ]^Jh"m9hFOJQJ^JhF,h"m9hF56CJOJQJ\]^JaJ&h"m9hF5CJOJQJ\^JaJ hF5CJOJQJ\^JaJ hw 5CJOJQJ\^JaJh hF5CJ hCJh!CJaJhCJaJhVBCJaJh`nhFCJaJ hXCJ hFCJhs`0hFCJR$S$$$$${{{{ $IfgdFzkd$$Ifl0|) t0644 la$$$$$${{{{ $IfgdFzkdS$$Ifl0|) t0644 la$$$$$$%%m% &Q&R&|||wwreeew 8^8`gdFgdFgdF$a$gdFzkd$$Ifl0|) t0644 la R&&&&'Y((+)9*+-////}}gdF^gdFI & FEƀz.gdF 8^8`gdF 1$H$gdF^gdF$a$gdF,,^,_,`,x,y,,,'-(-)-7-8---8.9.:.R.S...;/5F5d55lcccc $IfgdFkdV$$Ifl\2 H$ Z Z 04 la5555555555lddd_dddZgdFgd2/$a$gdFkd$$Ifl\2 H$ Z Z 04 la 5557777777777777777777777777gdF 7$8$H$gdF$a$gdF5Q7U77777777777788*8,8.888:8ɺvmvaYGa5a"jh{rCJUaJmHnHu#j|h{rhWCJUaJh{rCJaJjh{rCJUaJhF5CJaJhyehF5CJaJhyehFCJaJ"hF5CJaJehrhnhF5CJaJhF5CJOJQJ^JaJh{r5CJOJQJ^JaJh2/5CJOJQJ^JaJhF hhhFhhhF6OJQJ]^JhhhFOJQJ^J7777777777777777777778 $IfgdFgdF)$$d%d&d'dNOPQa$gdF$a$gdFgdF88<8>8f88sjjjj $IfgdFkd$$IflF |)_  t0)    44 la:8>8@8T8V8X8b8d8f8h8|8~88888888888888888888竟sasOs#jh{rhWCJUaJ#j^h{rhWCJUaJ"jh{rCJUaJmHnHu#jhh{rhWCJUaJh{rCJaJjh{rCJUaJh~(hF5CJaJ%jh{r5CJUaJmHnHu&jh{rhW5CJUaJh{r5CJaJjh{r5CJUaJhyehFCJaJ88888 9sjjjj $IfgdFkd$$IflF |)_  t0)    44 la888899 99"9$9&909296989L9N9P9Z9\9^9`9t9v9x999999999999999ڽڽڽڽuڽc#j|h{rhWCJUaJ#jh{rhWCJUaJ#jh{rhWCJUaJ#jh{rhWCJUaJ#j2h{rhWCJUaJhyehFCJaJ"jh{rCJUaJmHnHujh{rCJUaJ#jJh{rhWCJUaJh{rCJaJ& 9 94969^99sjjjj $IfgdFkd$$IflF |)_  t0)    44 la99999:sjjjj $IfgdFkd$$IflF |)_  t0)    44 la999999999::::::(:*:.:0:D:F:H:R:T:V:X:l:n:p:z:|:::::::::::Ͻϫϙχu#jh{rhWCJUaJ#jh{rhWCJUaJ#jPh{rhWCJUaJ#jh{rhWCJUaJ#jh{rhWCJUaJh{rCJaJhyehFCJaJjh{rCJUaJ"jh{rCJUaJmHnHu(::,:.:V:~:sjjjj $IfgdFkdh$$IflF |)_  t0)    44 la~::::::sjjjj $IfgdFkd<$$IflF |)_  t0)    44 la::::::::::::::;2;4;6;J;Ἢěp[F)hF5CJOJPJ QJ^JaJnHtH)h{r5CJOJPJ QJ^JaJnHtH)h 5CJOJPJ QJ^JaJnHtHhF#h hF5CJOJQJ^JaJhF5CJOJQJ^JaJ#jh{rhWCJUaJh{rCJaJhyehFCJaJ"jh{rCJUaJmHnHujh{rCJUaJ#j$h{rhWCJUaJ:::;;;;; ; ;;;skkffffffffgdF$a$gdFkd$$IflF |)_  t0)    44 la ;;;;;;;; ;";$;&;(;*;,;.;0;2;4;6;L;; < ?W?? dd[$\$gdF$dd[$\$a$gdFgdFJ;;;< < < ? ??)?V?W?????@@A@A ARASAAAAABB4B6BtBuBBBBBBBCChCiCCCDD/Dڋڋwڋڋڋڋڋڋڋڋڋڋڋڋڋڋڋڋڋڋ&hFCJOJPJ QJ^JaJnHtH,hK&hFCJOJPJ QJ^JaJnHtH;hK&hF5B*CJOJPJ QJ\^JaJnHph33tH2hK&hF5CJOJPJ QJ\^JaJnHtHhK&hFPJ nHtH/hK&hF5CJOJPJ QJ^JaJnHtH.??A@]P & F ddEƀz.[$\$gdFP & F ddEƀz.[$\$gdFA@ ASA]P & F ddEƀz.[$\$gdFP & F ddEƀz.[$\$gdFSAAABQP & F ddEƀz.[$\$gdF dd[$\$gdFP & F ddEƀz.[$\$gdFB6BuB]P & F ddEƀz.[$\$gdFP & F ddEƀz.[$\$gdFuBBB]P & F ddEƀz.[$\$gdFP & F ddEƀz.[$\$gdFBBCiCCQP & F ddEƀz.[$\$gdF dd[$\$gdFP & F ddEƀz.[$\$gdFCD0DDQP & F ddEƀz.[$\$gdF dd[$\$gdFP & F ddEƀz.[$\$gdF/D0DDDmEnEEEGG=G>GGGGGG±ݱHHI-./0235689;<BCDFGMNOPQzܿ󻳯hHCJaJh0JmHnHuhH hH0JjhH0JUho,jho,UhFU4hQ%hFCJOJPJ QJ^JaJmHnHsHtH,hK&hFCJOJPJ QJ^JaJnHtHhK&hFPJ nHtH1DnEEG>GbGQP & FddEƀz.[$\$gdF dd[$\$gdFP & F ddEƀz.[$\$gdFbGGGGXHH./1]QQQQLJgdF dd[$\$gdFP & FddEƀz.[$\$gdFP & FddEƀz.[$\$gdFal of Chemical Health and Safety (submitted).     PAGE  PAGE 1 Rev. 3/06 IBC Protocol Submission Form 124578:;DEFQRS{|}~gdF^gdF &`#$gdFz{|}~hFho,hHh chHCJaJ61h/R :pF/ =!`"`#$% 51h0:pF= /!`"`#$% 21h:p{r/ =!`"`#$% n:no `nu?PNG  IHDR7cgAMA pHYsnu> IDATxyPCZ]x %( JQQZ bժXuB#mG."E[CS ?N~ D.el~AQ B!B!ԯ]B!B!BإB!B!BR!B!B]*B!B!KL&d]Eod!B!` 8mmmMMMT/&&& uKII +..Zz_~yIұ8B!hb{E pw9dȐ|+@PPPpp{{""" 22޽{999:NLLdXloooiiԌx?*{𡝝]mm̙38Np8 drxt'ɥ@sss``@ zo<ߓB!a uIvvvppիWNp  \\\o߾ݕ F^^+g@":uӳzyyM>}޼y^k>|[^zymm-455u+uTToL&3>>~ѢEK,?[ӺoZ=!B!17л>|:'''666=====]"\|9###((gc 4`lٲo=&)lmm[lSSSWWW޽{\.*;ajjjmm ~~~CU<\6m6---011quued27n>>>LnwȐ!uֲԝ֭ډ!p.--ڴչrB楥UаͲBS&ⶶ66?'''((&LV°ɳݰձձճճՖc4!\*ΡCc.{08@鳧;rL׽hѢׯ<}hj=< !B!B RNeffw : sЋ/$رc; x\.wrrRz /1jԨKfeeѣʅ aŏ=bX3_? ,PHMMmnnQu&33LLLƎ~r YSS%:##NiKKKknnvrrp8uuu(###Յ#O>bHL.խYƍ9rL&8p }zIIIEEŀKIII3f̘0aBQQQ}}=ygS1oSS6(//H$t.XB֦( *++|ԩSo޼y]LV[[bŊB!BIBtyHΜ9S-[FNijj 2e hkkz Hokk{ŋǍG9rׯ\++l¾ rٳݝϟo˗萰9sbzljU7mڤ>C666.\ձg622";"ٹ*ɷɷƲ";###-ܶO٤RM*3335ǎ#>>>...#J8O<;Y]]MQTRR% 8q"y7l@inn&7uٲe'N$iii888Br]/^>|8p[VV3fZǏ_Qcccaa!駟)*((`ܸqO&*B!B.g}.… nԴiH777!!!G x&MdEٳ;~wRbd 6PUZZJb ϧ{o޼!tD$@E)9rbbb܇T8III$=ڪ֖]OTF644---)jiiikkv(Zr%Ik.{{{@J?'OR$]!bJoܸC322S[[KQTZZWWWlϘ1N0gWSSa=25''}!B!z'RNijjKA VTtGQL&pR3G9o<7DU( (jӦMjC] pttTNGgYH$́"'ųٙt[FQHH.dٙd_bbaÆX,F'300z"bcc/^QQQtFLo5У)VNܽ{~H666K,QsB!BuK zظ+9sw鑍+Wн3URTqRD"ټy3ym8{,fiiyԩΖK5kVhh(EQ](EK,PrÇ-g_V|#r⫯ :`uuu_%I׮]bرc%nxo޼IJJڴiNYYYAAA|||D!B!D/XNmٲlYNSRRhjj/_zxx\~`R"zǏ744(!Hۂ>ښwssklln555jժE  ʼn⸸8ssӧ>Ԝ9رcG}cDBP(:999$!!޽?+!O>ի;88رb1»uVչȑ#F"!P9>>><{?MgϞ׫yE|||!(Dd'IYf%&&r%ט1cjjjΟ?ojjZ[[ۭA/^------wzzzL&Y5'Olŋ JJJMFUTx7os8={]7:;;1JKK"))7"B!"K:ennnjj mmmS蘝'I:tŋD͛7Nb2/_vvv{@ חH$d-!Pka:˗ RRR455 mmmg]De0,p8>'¯^0 <<\qSXz5YgJ(bR>d?S2\.ollx顡dgTTƍ{\]\\ɓN1bMIB!B]*ԩAyxx턄:=zH__7^jժLpuuR`0NtR77ѣGWUU={X!DEEU2QE?q̜9,{TRR GpTd:\zT.Ϛ5թ/ϟ畕@]s]i5"OQʕ+;[ !B!Pwa MMMJyZZZΞ=̬7.\H]FDfܸq#99ijj"}(77'O^|9??Ejoo1 еk,d{ҤId]v(u֭[GE ̜"3R\.'3}߯& =(""B*`!!!hG Tx[Ӕ7lؠt֭[[۷o'7 gggD2lݪ*7nöm#D` =᮱Qq?=k̘1] !B!;a öm 4446nxʕ$Dbee5c LfnnD111666lmmr 1YU=::9d2CCC|>L>= e 66h .aÆ;wЉk;;xX࠯|Ç6~:ܐXCQRo̙Ȱc%%%Æ p8ӦM3229r,+@e:::EEEd3gΨgDf*'$$l߾]I֭['Ν;giiYUUuҥoT/xyyW>>>cǎr\.W[[000Pfffk֬} jkky<uuuSׯ?ydTTTXXjpB^)B!BQuAUUUrr]D=* 'N`08@ ͥ(*22Ȉ?~<&&F1R(777fY~}qq1]CVVܹsKX,)"I$:֭[s[d(+!ߕH5_VVcnݺ"5#TfggRVVsNc΃*p/[Ni-H%YT\cdJ! FKRtDq!q!r,w ,:ČSfpu΅"{|EFmذ!77W$۷O4^PmEFFȲcǎaÆ)Kƍsss3'N8ykW9s ʕ+~ٳʔq^{k,))Q~sAoo9GҥK]t߳gSK9bƍF p8MfbȲ|ZUUeە2Fufuu,=zPoѮ,'evZZڶmۦOb eSٳ _[MN+nY~Q+`6-r^oq|Gewzyy P[[+b.]r}>USSkVUUy{{+[{mmsMMp8zFݻDQ tȝQUS'%%?~pY*tiiiIIIwӎ8gHXXXiiǣuјpBO}I< ]299t4o޼-[_q.TT?BA^|ťK>Çt$.QE1##cРA?Ctt'ԑPY/^O̔$T۷ΝkjtX[ F&tҥ#F()'AӝlÇթ#AAAOnٳgf}nݺUWW 0/R5f5ԿRd(111NRGVc"""y~9sy扉9~VYZ*6x`5E3eʔFg?^[3}6((י5kQ+DQVE4TZEEE(QQQN۲eK׮]>}VH{t4d~ҴPG6lXS PPP-tÇg׮][_~Q9rD-A8q, 8}tm笊 Y*2eTTTlllMII9zґJw%VYMj^m6[{@; Kp)r*] k֬QF+Z.ZH{e0Au̼uV{@[#KǞ;C;֭[v*BXXX||vҵ N,<@[ rS5V5kh/E -H|||{9`PPv;R?<[րպ{n ΁,[Nk׮^.X@wޣ&`0hϜ9 CNN.URR2bR@?!$СCl6[]]CWp`[瑄͘1C;ҼNV_~C1o޼7^vM;VlmٲŹH9~NtdVVkzzRBtRIv:-Z=u5P!44444%aTTT|xAAn׮s+V=|||JJJ f"ijj-**VGDQ9r;t]DQFQݸq#77tsO>W]]ݦQ4Aeg5ov.јkXt#66VE `=ze˜9w܊+KYoݺ~CflK$!NQ” D@T t ""^ZUDV("ID.UZc[F-we@Qߧp=g7g}jĻ611!7!Rr#:kqkf5fCYü\. 3\|+3@Rq8Xӳc___RrG5ʂ6OLR jo!$Żw޿hfU*%%%36ښOfÆ Ȗ}m۶xBVWWϷ״ǏKR I&:tH*?|>ȱʁ#355J%Kx< b۶mGq !5 Źs>|p4-MLVV֪U֭;s qpHHÇO G*j2\,[[dcccwwwM(55uΝ|>񩫫^r7ǰձ՝Ǐq$>^n߾/Ʀ?"Q1eeeݻw2oGG۷owww=qW&Υ555jOZZrϟ?eJ9++a^T*BBo#B(;;;;;[u֑w!PH5k֣Gx 蒥"Ftvvj;uvvĈD"\NfD"L6gm#G_A Yr򒠃C__RT{J BAQBtt5s֭ɓ'ӯI?nSSSr̼y]R!Z. /7 N={,qRR:::,X@ʕ+Gə,RI>RiZ3BѣG::: BSL y ^-9{LܦJ:y򤃃> <עER7oUUU _ vY*???АzƌK,INNf&m&UQT|2e|>L 諃cRa#OtܹOy&. Gv|˗H$bkגc&M222`"DF C=Z[[p.9yzzJ%2o}}+CkeeeT...MMM"F:BjckN<88hnn>WWWЃJKK KJJw9#D"Qss3''/_ #3g#gǍ7MDڞr-((xX… 'OxCCCNNE6kH$.6bbb(3޿ٳgďׯ'ћk&<= Lm4NNN'NG}:>|{ԩ!4k֬Pm'f7777773d2YiiJ}cq'⢣;;;A##ׯ{#-tp8^^^ +NJJ~iPPPcc 8ζm:::hkk;wV)m]xcgggHv7}YFF+:Аepss+<{L.Sviboosjڲ^bO?DNTc[[ӦMa^oTj~~ةT& b'8˽t:B]**r$,PLLLMM ~R)ntgppܝjpss $ܾ}eEn#>MRӤ z@m-YQ]aZ}7nljjug/''xҤIĈ3%wsSSSMM B(22\u̍ď/nذw].700000pFFFF}}}...:FiUJLL$zofnn㼼S_^mS*$8(#---j#quh:R!ۛݻù:/ Vr̙3. |>ҥSNϸ#=;HRRRRbb"B(444(('Pruu*,,&x#$M4UQ)ʀr*}}`(,UT JBHII!R? BP\N +Ju}v8Mi&D+33ŋjצaϥ̢tBHT^z…III:O:"##+HZZBӸ# ;Hqqq@ 7c GGG'']v )H*I}}}bjii H,11QUWWW^^<==} ~L&𨮮p'\kxj3g!Agg' RSS{c+WPN_***t~wol:t௫!dmm]^^ZW`B.pB|kBB”)S**]4E*5kԌJT ]ի&W=00@\xqee%Ԙ#~

>Kzmx<ܹs)ZUQ#9WMM ,H$jhhx[mTQQ}?XXXYr<""b̙4~nܸ1yd`rr2nY6 3?644L쬧C .\~@{{PD:6lmm{zz?nooO?YSSr'88xԩz~xidsawiUsmTLL**;;JzסXnhhvA988XB300_?TJy?ȑ#G c8QTTyD.wp8/mܸ1//R9EATTTee+m_#!!!{&qlTTVVP(ȅ!o{&%%Gi>z$Jme ͛7/_ֆb:T$988xzzVWWw1T/bhsss\t1i:_eUϏ͹G}>Q,i 孭sa.p8߽8)))Uttg}fkkKFݡb_EA%_ƍn믿޿1C̱cdžB;waR___9hPL&KNNƟq uaCCC|>ݝ|AAAR$;**c߾}+=E"]] ׃y}IPГ/o$JN}mHzebWE5iӦnݵkxlL&{h  qWժ<<<"""OJv.\_[[{իW3DY*\KR=y򤡡/T744`a ”JISmkH2 !dooϾJm2… ʪukD_s:dl\rŬR[35&(jkkF 233ccc^s,WxԵx钥z[ 8ij1{>}666j#(422~z[[QKK˗/H$$ ӧOwuuewN)((xe˖W(v.S\KK BԔMD"DR_MtƠԩScxA@,T*-@*理XF]vMm 2K.H]Ze``KfË/d]!::ޝ;wbq?X[[ۂ zzzB666փ?466RzuQlٲlVH)IIIas}/(6V\tqqqo{PTw{aA.VNӯdYR h,92RaHM$7#rXfl2ȲvNgN]@>?λy?9?<8::Xm4M?CCCg9뚻f|ʦ4 dDFF"JKK-ΜXx1BH?3eUzzɭqNJ3_UT[QQ'5((jS̿Q۷oohh ʊ <966f2(Җ-[.]$tnn.{Q.77۷o[/Cs2ÚKKKًW_UTT0IZ88BJHH_nݢi^c7o˜|2 ;%IlӦM===(KD=7oޜTUR>CCCL.//GVdb]EJeSSSyyy]]|+WjvLg#3Bj8V ?GD[[hced+F^RqKMfCCCv...{X}&w#+44mgg`>˿544ʰa0W^=|uб'аٶڰv˗/啰³=<-^Xv -ya ?GFF,Μ NvKR7TWN* 73JDgmݺujQ*0;FkC4Mjj*'aEQ DFQA===iiiX,6[ MWSSSuu5+6 Jpb t5Dbkkˌ:uJ$I-[ⰰ0ys͛U*[裏GS$E"B$Ib chgyD࿘h3g#[o((GGG8DJ[:99I$w _KRVc$Io{{B`>;y$R9|||\]]NNN$Ir+9|hhs缽NIIYL[% &E5w܀~sFtRvlٳg)*N,FvՒLXxyy͙3gΝVX|MqD" =ŋ ;vכ+ 0FfƆS9bNffE)?=gǎ8e)6vANBIII]]]TQ Dnnnf/ʕ+3337VTT}eee*$bO;v,&&&--mG zEUWW$aÆqТEVUUDhv;*s⋍7S4M9sF&4m0\]]9afDӅ~waRx{{sVrJQQQVV>4WTQlá IDATůRر?:s`b*y 1,B(44TP_^T>g(3 Eppp44[ REQ&LF&IrӦM---!c~~~ /|rX`M1`Y*达>ѳ4ӣ&>q!H|WAG oO5^p9Qj޽Vwtt; ꫇FъK477 !{]vM,hkkx"g0))rJmm-{hɱSuOBٜդgW]]]yyyII\.ĵf\82,A˖-knnV*xxxxttNۻw4ɓoժULK)>&&=ria=?%T*pႏs}WW?g^\\Y%==smXFFFJJ MFt"(00lKLLN9߿_&UVVVTTTVVBf M 믿vvvJR 8OؙDSY^^Xf{gg3?22RV39Z->lkkc{HtrrmllZ-'LGEEuww߸q&%%%$$xxxp ~uZm2ENQADss3?Eŏl.Emmmkii!ijL?ub*T[vmdddxx5)*k<L !PWWl2i5 N8V*~~~qJ L&cqӧO3)\~S넹߿* UT|e5iS(S `ܛeJ};wdgpG*Ӌݽӳ9߯\o) Egg>\ٜ8j:==`0p"[644R)J^n~JOOg(N(N*ngggfG3*LVQ)nv_Ee.޽{% YTeeegNڵkmllU@{kf8JsHdvvT*}84b0c0uX1&[E(J95Jڷo{wᘶ(J icǎZ9[OUK---MSJ5>>^RRιtRFcPPeyfҥLl߾܊Uppٳg91#gddSWbظrʕ+Wrrp$%%iUVݏ===׮]H$aaa$­[Ν;'Ji H$ԕԐ$9113);BM3܃w1"s7o}:''_~D",s̙FIҮ.&pdFpLVgϞ%Kp.P.766hnR4//'3 b8//N*~7?3BR{{{ܡCjLRRxRLOO|rrrvNiMF111qddD$Dj/>Sgȑ#555̎pBi==]]]D*JRDeYz|BHrt8|%%%XSS?RKji~魭AAA! IHH'N0K_^xJibX~ږ/_nD y7`oիW}v%gHcD"X\PPO?Y3O__ߊ+p/&d}kcjBCBBFGGB.\`a($I$mۆkp;gVV۷/^ {aaa۷!p˗/=brLhJJJkk+Kᑝ=22e2Y___jj*sʡC?CYY+xׯ#D"MaaYj HLLbFi.]?nllD4m0^u Ե餸9"##9qRTK/-]~D&\]]S|ZIr-UOOS844DQ{h4 ˖-3b]]zn߾-sryGGgN__;5#ZZZ((*$$y+lmme/_ Liz||<00}Z67ȑ#̴lv(NǙ?innnnNuP(:;;ϝ;&W?pœH@||VPT` ;u;VWWHj;3­ʭTZZԔ'\r%88}UUUlpUUU*iV%࣏>b-FP߱-D!ɳی޼7:͚5rԲnݺ"L+²X%뉷ɾy0??뾾=;ڰ᪆.7|ɓ'ӧRݸp!,J5ݻw<*Z/#+++##CΝ<zѥjI9p7777J UkRJ2BTs RCTnnn7TfQ&Mo e0\K'''ڻݷo`u˥277ڱcG`` Kb2*CEUUUΝ`.< HLL1lƌW {45&>V>`PDTDD-,ORikk;y$Bѣy\.~ '[[[F~AssLMM'[xi‡#iz8\J׳=,,Ʀı.<<\9;RH$...AAAێjMd'߿}d2UetɮREDGGǢĒB@9_S!¼}N>],)/ұ~Bas Ԑinq/˥s$3Xww7*JGd===BTd YJWWWGp8%00v~Tԯ|>ŋʉ!iiiqqq\Jnnn ,A.>88xHUNSZZ̀ cڴi*k㏽%%%999YYYd.&5G]&lںukSSe߾} +**'ɶmvE~%B"7oܲe B/7oz^m _ŧQ\+V|wd tij>%ʷɱп6zZ<JLLk$/߿nnnbqnn$B3g$VSI*fdd'} <\.r劺nnnٙZ 'Nx9+7ߴTTT55knnNIIܹ[$_eUjkkBQ!Zp8ʷ9r$sL(Dh>ܳҳf%գq-Ǵǧ^󫯯<}$mô655hq2Kgg ={uUVrN2LeI#>yI-$?M"B72H3b[D"˗ [ 2@@ҥK/^z#Ax%(=jf%ߑAL{E޽:=YGӜЇ*,,|15 fHElllqq?3!!!"H$x)8/LTŁl6f755R-)).>5"88ZuklJ_}Spܠ jڵk5EQ2XBBȈr{ww`j[[[HH"Jϟ?a"Tqdf;99r <|07nܨa,_VRI*_9F`jiiiԖ&??? 466 @  % \*e "<<gˊҀ ӽ$544PwL+3zp5B[l1aմK. 2yRUh= )dtR Uԫ___ YHfffԯԜ<ՂyH eБ걃'"/gggڽGI.⸸8GGG}T@ P Ty{{rCU ZA% kS~-cccAܻw vٍoRT*wTԌ$l"wꪯu{B>ORG UWW  Zr ʥٓg B>9L&ݺݸ\ݻw\]]ڔ_Qwww]]YNJq[nA˨SN +_M믿2BIII\OpbDd;JE訯'Ⱥ麄4Gݳixyy!5>|ၴ5Js|}}+++ɸ K oֵ$ǕG/t޽RKKKZ-{{3ff711&bΜ9bi-FDOO-qŅKݿ̙3ִ/^x111f͢PTTd3LPH}?7oTQ?~liiQy2ŋMfbb"O9􌏏'Ž?>00`?`\D!Xkoo/^,JMM======NNN+W$̢U4rB`2-,##珏o-\pxxPغu늋 [B('''==]C< FFϛԌQ{FDDX۷{###U`0>|HΆ 7*?LrT+ ƳgȍvvvQQQQQQBƍ!2 |wFFF8Nll@ P^9^3mL&UO1sΝ;[nаTz sssZ]v%==}ڵbڵk׮]Ogx0 . zjFFH$z왃2L&E%hi\bJKKcbbt_3X,7o^WW򥲲蘘3g(_MMMݿ"ÇhfT^r\." 3LZ +R)(q2k׮矴ЏL&QNV&br/`nn^UUcǎ@DBdiiaÆ̮GLь)[o2J.]UKkJ;{{{___ILYF"֎WTT$''=,""ˆM1OOOOO ŋe` gT IDAT999Z! . dp(u+99~+L'''WUU򼂂pUɰe˖ ZO9zdi*jcnc:?-<ɢl?l J(x犀Qp,˒%jT`<€9 EQ@I;(OB)(sKm:TJX-ӇC Xjs \u1w ?~iiiKph%e"8p/Rfچ6cgg?G,1-?ɓǏ[uslllLy988tvvrTO'?~)J^( R )d2L&cz-,1##xd#"##mw6WۻU(ߧO19pp099]9**bO]]]&/[ӌ[RuThK˺L۷o&>l+W,SeeF%/_adX) 5{{{ƊqW疖w}wBZ_u\]]5jjjm۶-^5rlmm t*nL.!rB2YJMClMѽRZMdTtM2*%<==]$ߵ̺(աC:d䘘)k 4g___VBUUӧO222nݺРj}}}S& +((IkLғ'Or\.߶m09ŋNNN===Oϟ?oAfk׮;mpp+ ϪQdvvmt:GW4D"y󦛛ʳ...ruui:448|P"0iVrss&Ϟ=hkjjOgDAᠠC9sfC,3rsrr^ilmm+++[[[ QBԁ2ȢҧT*ǝ %YNl*nuuu ~zB`@@@KKqVSSS}}=EQLU[,몧3ER?  +++~Ku_Jq4M[BH %յ J2noIOORÇ^:99988믇'555S .JŠi널[[s΅]vBBB,|Ux<^LL !drrߟf͚psLNNة)&#-FSQQaIj D~6!ӧ555&wttkx:KYj޹s皛R)M)))bxժUE4=oWD$UWW3=&&&ؼ*>_]]|d ڵkzz<ܼci~~~FVOOO[[0&=YS&jZsUD"T*5YNʼnE]|x>Ν; ;NST {f͚]vjTjnP(TTv峱;z</$$6(HvܙMө {W$i43gx{{nDbIg]? III{yyyKK !/++=bccKɓ\PP@QHRyyyR挌ξ[ׯLN([RX%%%枚gӧl0@ϟgdd-QD={&RSSggg4 Q*BHvvvaaOoxxx֭W c=jkkUUU{] !:uc‚O~-[h4BB@i*X733_;)44tÆ "%%eǎ{eCT FW_Y{&TI믿j+<==#"":\SϞ=h4}}}{K}yyyB޽ܼu^),111Zߝ;wjkkݻG2iӦ}/ Dt{{{{{ڵk) /UQQfoo_WWg3{qƍ7o.]Z"uQ*@P( !]]]s||| !&x<@`ȑ#7o>|ܜB$=Ƌ.Jekk˚q># +++ VVVrZ,++rZ`=66P$&&ǕFGGoݺT*}H ETTTRR W^e-9ReiEEŃ ϿpG}ѷ~#EZjkk Rw{yyqOc(2~=44O>ӒŬ?hLf2Ai7nرcb`jx%4~{zzyTYY077GL5wJ$Ŝձ.JAiI߿Zm\Cc1QǏsssMMMiii ^Bf˖-~~~nnn۷]~=,,l[,nRfNJf+uQLooo@ J;;;욚؂MCCCr<>>xG[̌~(PX\\,J n9sȑ#V닊rvvV("Doi(,u1ko400PeddX(J5::ӳk׮GJŋEEE===|>ѷ5J2ϳK!;60?ʚ2,8/F<b?|itW\ٽ{;FFF633Ƥ2߼;#,JQ*{ٶma"R4...!!!**Q1JKK{YÔ!ܻw/22`eWW׬,s딗jKv4I.߳ӗQTT?Bttt43ff ̈a-#2iȱ cjl+..Q-`cwԱc̅hiznn\C BRgiӧOoڴoqqq۷o/,,S(IIIUUUJ22ŋ&Nz}T* ؝;w꧛(cvuu B>4=99FQ*[n}SPj:((hhh1P*[l蔗?b]dd$w>s322Gh Qy{{یo t:WWIB RRR >4W? `e:Jeҝ;w O***BCC׮]knTzqgWW׼&c[1r\$1<<|eTjdk߾}.]27 e}srrdavx9994M3BV{4ooo_rp޶J 3٤_g锔 jYYYm7<<9c&jiZvdX,N8ac{1k% Dx<ȠP(i!*vt6Swww3cgϞ߼y]+bszzz~s >GQOx!!!===Z1rrrدe@|>dl2ehq#DEEm߾iaa'stlT%%%ABBB6BQT}}5lVfTqlj1- +ޭ-(ɧLvP(de ;'2ǟIWN_XX{;\r{Ŝ_J,q1wE/_D{E o.3 t0&A&fӋe3"-s˒ijjjll?0xb| 6BJbG?fTEEm޼ybUUhFFwT~~~S)))!GqfP/BE쪨t:=qot8;vt缐DS)**b'X1 ht0 #˟Dт bQ( ^to߮t---w}wѢEr-->""c Is%&&vLI; ?22IO]~~mNs…%y<^HHhdW\ Rijddd…Nĉ bٲeuh4e6cbbz{{ߓz?g4z$B" @>|&\.bP(RհսM r;={T9~all;'^K5fxZhѶm>L$tttӇz>f1f}w0t8"j+\.l6 BoE0OUf0 S\\̮ե݉DZKE쌊bÛT&z`NNS5SaaaK,ٽ{2h.`0Wҕ)rO2)HzW#a-UQQQyyJhhhWW͛7#""h_DDZ6v}ʕݜhgl6XYPP00hVx>I p8JP̴ns80 ;=txAaa0x<^cccJJ !M~DV .{?w";vٝ0LBB?~ϟZ/lhhٵkdCCCX n5Ef[EUCC;CaTl6H,Ydttdg6ul6BHMMMzzi[hvy<[(rf?yʝ{vәt=++^^ds"TVV~jR s%''/X@d?8***$$dw4e4۷x⎎:Ŝa߯mfX֭[h\.^y789y;yyyWWVV6ftEzoz"+J 9_QQ1;%˗kjj.\@3DtA.EuرLŲsNV[[[[\\r*++@>fKT[Ϻ'4H$xǖn@rϟ?G;u!DRݸqC7n]xaaa8:jry۷8N.;44$ i^LR-_<==RWWǞrxrSh0<***ت(g4P*b=? ORTa8z([][[_?~O?et/0{ժU"hlfQB>+VjZUU+Z N߿b5 =ȏy v"H7DGGx<,UppVr.^h2= yCCC@@fJ}CEf{ߌУFSRRRRR[ZZ"##5 ۸>oBbcc&i]SRB"""bbb)BHgggff& !aaa}!dƍt2h 񉌌tt'Ϝ9xb>/J\H Z`AZZȶm"""^;wBnG֭h cǙϩׯGGGK7nܺu.8p^;@q=P>^WWsΪABHmm{2Lrmc&88ѣ2l~|>8qoٲJ$I{{; C|~pppOO!$77j``fx>_p+!j4ճ>jV]]= ڴilx6 M)Rbm A'!!AD DB$6`Dl, %/$ CUwx7}&pSg>ğT!x<U}MQvvve|!z}}vU*:?'ѴWaqq1ݻrpvv?YG_i###Qdr|||jjjuue԰nZTpnn}V6E]l6aGGp ?ӛ喖CT꪿bdꃭƷ'BP|~~noo9Дo5ooo*0888 !$cS n՟/t4N =??g2@,Uqcc#j@ujZ^\\,//JL&뫯obV|滥T5\n}}!jۓ|~ll,j[okkKkkkJE)UrfflTS xTꚞގ$VrJWVV~o>KD ֓RzR*ZOJ@Ih=)'T/Ҷ|IENDB`xDeCheck166xDeCheck169tDText1tDText2tDText3tDText4tDText5tDText6tDText7tDText8tDText9vDText10vDText11tDeCheck3tDeCheck4vDText13vDText14xDeCheck157xDeCheck175vDText69vDText70vDeCheck63vDText17vDText21vDeCheck64xDeCheck170vDText19DText20M/d/yyyyxDeCheck171vDText68vDText65vDText66vDText67vDeCheck66vDText22vDeCheck67vDText23vDText24vDText25vDText26vDeCheck80vDeCheck81xDeCheck158xDeCheck1726$$If!vh55T5T55555#v#vT#v#v#v:Vl4| t\:+++++++55T555apP-kdR$$Ifl4|ִ ,lX D%8``T`T```` t0\:    44 lapP$$If!v h55T5T5555585 5 5 #v#vT#v#v#v8#v #v :Vl4| t\:+++++++55T55585 5 apnkd$$Ifl4|  ,lX D%|)/48  T T    8 t0\:,,,,44 lapnvDText89vDText90vDText91vDText92vDText93vDText94vDText95vDText96vDText97vDText98vDText99^$$If!v h55T5T5555585 5 5 #v#vT#v#v#v8#v #v :Vl t\:55T55585 5 apnkd!$$Ifl  ,lX D%|)/48TT8 t0\:,,,,44 lapnxDText100xDText101xDText102xDText103xDText104xDText105xDText106xDText107xDText108xDText109xDText110^$$If!v h55T5T5555585 5 5 #v#vT#v#v#v8#v #v :Vl t\:55T55585 5 apnkdT*$$Ifl  ,lX D%|)/48TT8 t0\:,,,,44 lapnxDText111xDText112xDText113xDText114xDText115xDText116xDText117xDText118xDText119xDText120xDText121^$$If!v h55T5T5555585 5 5 #v#vT#v#v#v8#v #v :Vl t\:55T55585 5 apnkd3$$Ifl  ,lX D%|)/48TT8 t0\:,,,,44 lapnxDText122xDText123xDText124xDText125xDText126xDText127xDText128xDText129xDText130xDText131xDText132b$$If!v h55T5T5555585 5 5 #v#vT#v#v#v8#v #v :VlZ t\:55T55585 5 apnkd<$$IflZ  ,lX D%|)/48TT8 t0\:,,,,44 lapnvDText46vDText47vDText48vDText49vDText50xDeCheck159xDeCheck160xDeCheck173xDeCheck174vDeCheck37vDeCheck38$$If!vh5h5555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4hDevDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4hDevDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33$$If!vh5h555:#vh#v#v#v::V l4,5h555:/ 4af4vDeCheck33vDeCheck33vDeCheck33vDeCheck33vDeCheck33vDeCheck33h$$If!v h5h555h555v55 5 5 5 5 :#vh#v#v#vh#v#v#vv#v#v #v #v #v #v ::V l4,5h555h555v55 5 5 5 5 :/ 4af4:kdT$$Ifl4" LvF N +hhv:,44444 laf4vDeCheck33$$If!vh5h555:#vh#v#v#v::V l4,5h555:/ 4af4vDeCheck33vDeCheck33vDeCheck33$$If!vh55 55 55#v#v #v#v #v#v:V l4,Z55 55 55/ 4af4vDeCheck33vDeCheck33vDeCheck33$$If!vh55@ 55~ 55#v#v@ #v#v~ #v#v:V l4,Z55@ 55~ 55/ 4af4hDevDeCheck33$$If!vh5555#v#v#v#v:V l4,Z5555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33$$If!vh5h5@ 5 55#vh#v@ #v #v#v:V l4,Z+5h5@ 5 55/ 4af4vDeCheck33vDeCheck33$$If!vh5h5@ 5 55#vh#v@ #v #v#v:V l4,Z+5h5@ 5 55/ 4af4vDeCheck33vDeCheck33$$If!vh5h5@ 5 55#vh#v@ #v #v#v:V l4,Z+5h5@ 5 55/ 4af4vDeCheck33vDeCheck33$$If!vh5h5@ 5 55#vh#v@ #v #v#v:V l4,Z+5h5@ 5 55/ 4af4vDeCheck33vDeCheck33$$If!vh5h5@ 5 55#vh#v@ #v #v#v:V l4,Z+5h5@ 5 55/ 4af4vDeCheck33vDeCheck33$$If!vh5h5@ 5 55#vh#v@ #v #v#v:V l4,Z+5h5@ 5 55/ 4af4vDeCheck33vDeCheck33$$If!vh5h5@ 5 55#vh#v@ #v #v#v:V l4,Z5h5@ 5 55/ 4af4vDeCheck33vDeCheck33$$If!vh5h5@ 5 55#vh#v@ #v #v#v:V l4,Z5h5@ 5 55/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33vDeCheck33$$If!vh5h555#vh#v#v#v:V l4,Z5h555/ 4af4vDeCheck33$$If!v h5h55555555 #vh#v#v#v#v#v :V l4,Z5h55555 / 4af4vDeCheck33$$If!v h5h55555555 #vh#v#v#v#v#v :V l4,Z5h55555 / 4af4vDeCheck33$$If!vh5h55#vh#v#v:V l4,Z+5h55/ 4af4vDeCheck33$$If!vh5h55#vh#v#v:V l4,Z+5h55/ 4af4vDeCheck33$$If!vh5h55#vh#v#v:V l4I,Z+5h55/ 4af4vDeCheck33$$If!vh5h55#vh#v#v:V l4I,Z+5h55/ 4af4vDeCheck33$$If!vh5h55#vh#v#v:V l4,Z+5h55/ 4af4vDeCheck33$$If!vh5h55#vh#v#v:V l4,Z+5h55/ 4af4$$If!vh5h55#vh#v#v:V l4,Z+,5h55/ 4af4vDeCheck36$$If!vh5h55#vh#v#v:V l4,Z+5h55/ 4af4vDeCheck36$$If!vh5h55#vh#v#v:V l4,Z+5h55/ 4af4vDeCheck36$$If!vh5h55#vh#v#v:V l4d,Z+5h55/ 4af4vDeCheck39vDText27vDText28vDeCheck40vDText29vDText30$$If!vh5` 55y5##v` #v#vy#v#:Vl t6,5` 55y5#xDText133xDText134xDText135xDText136$$If!vh5` 55y5##v` #v#vy#v#:Vl t65` 55y5#xDText137xDText138xDText139xDText140$$If!vh5` 55y5##v` #v#vy#v#:Vl t65` 55y5#xDText141xDText142xDText143xDText144$$If!vh5` 55y5##v` #v#vy#v#:Vl t65` 55y5#xDText145xDText146xDText147xDText148$$If!vh5` 55y5##v` #v#vy#v#:Vl t65` 55y5#vDeCheck70vDText45vDeCheck71vDeCheck51vDText38vDeCheck52vDeCheck53vDText39vDeCheck54vDeCheck55vDText40vDeCheck56vDeCheck57vDeCheck58vDText41xDeCheck147xDeCheck148xDeCheck149xDeCheck150vDText42xDeCheck155vDText43xDeCheck151xDeCheck164xDeCheck165xDeCheck152xDeCheck153xDeCheck154xDeCheck161xDeCheck162vDeCheck68vDText44vDeCheck69vDeCheck78vDeCheck79]DyK :http://www4.od.nih.gov/oba/rac/guidelines/guidelines.htmlyK thttp://www4.od.nih.gov/oba/rac/guidelines/guidelines.htmlMDyK 6http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4/toc.htmyK lhttp://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4/toc.htm DyK &http://www.absa.org/resriskgroup.htmlyK Lhttp://www.absa.org/resriskgroup.html$$Ifl!vh55 55=#v#v #v#v=:Vl t655 55=alxDText149xDText150xDText151xDText152$$Ifl!vh55 55=#v#v #v#v=:Vl t655 55=alxDText153xDText154xDText155xDText156$$Ifl!vh55 55=#v#v #v#v=:Vl t655 55=alxDText157xDText158xDText159xDText160$$Ifl!vh55 55=#v#v #v#v=:Vl t655 55=alxDText161xDText162xDText163xDText164$$Ifl!vh55 55=#v#v #v#v=:Vl t655 55=alxDText165xDText166xDText167xDText168$$Ifl!vh55 55=#v#v #v#v=:Vl t655 55=alxDText169xDText170xDText171xDText172$$Ifl!vh55 55=#v#v #v#v=:Vl t655 55=al]DyK :http://www4.od.nih.gov/oba/rac/guidelines/guidelines.htmlyK thttp://www4.od.nih.gov/oba/rac/guidelines/guidelines.htmlMDyK 6http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4/toc.htmyK lhttp://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4/toc.htm DyK &http://www.absa.org/resriskgroup.htmlyK Lhttp://www.absa.org/resriskgroup.htmlvDeCheck59vDeCheck60vDeCheck61vDeCheck62]$$If!vh55#v#v:Vl t65L5xDText173xDText174]$$If!vh55#v#v:Vl t65L5xDText175xDText176]$$If!vh55#v#v:Vl t65L5xDText177xDText178]$$If!vh55#v#v:Vl t65L5xDText179xDText180]$$If!vh55#v#v:Vl t65L5xDText181xDText182]$$If!vh55#v#v:Vl t65L5xDText183xDText184]$$If!vh55#v#v:Vl t65L5xDText185xDText186]$$If!vh55#v#v:Vl t65L5vDeCheck82vDText51vDeCheck83vDText52vDeCheck84vDeCheck85vDeCheck86vDeCheck87vDeCheck88xDeCheck156vDText53vDeCheck89vDeCheck90vDeCheck91vDText54vDeCheck92vDeCheck93vDeCheck94vDeCheck95vDeCheck96vDeCheck97vDeCheck98vDText55vDeCheck99xDeCheck100xDeCheck163xDeCheck101vDText56vDText57xDeCheck102xDeCheck103xDeCheck104xDeCheck105xDeCheck106xDeCheck107vDText58xDeCheck108xDeCheck109xDeCheck110xDeCheck111vDText59vDText60xDeCheck112xDeCheck115vDText61xDeCheck113xDeCheck114xDeCheck116vDText62xDeCheck117vDText63xDeCheck118xDeCheck146xDeCheck119xDeCheck120vDText64xDeCheck121xDeCheck122xDeCheck124xDeCheck128xDeCheck130xDeCheck137xDeCheck139DyK 'http://www.research.luc.edu/complianceyK Nhttp://www.research.luc.edu/compliance]$$If!vh55#v#v:Vl t655]$$If!vh55#v#v:Vl t655]$$If!vh55#v#v:Vl t655 DyK  yK \http://www4.od.nih.gov/oba/rac/guidelines_02/_Section_IV-C-1-b-(1)._MajorDyK yK xhttp://www4.od.nih.gov/oba/rac/guidelines_02/APPENDIX_A.htm DyK  yK \http://www4.od.nih.gov/oba/rac/guidelines_02/_Section_IV-C-1-b-(1)._MajorDyK yK xhttp://www4.od.nih.gov/oba/rac/guidelines_02/APPENDIX_C.htm$$If!vh5 55Z 5Z #v #v#vZ :V l (05 55Z / 4p($$If!vh5 55Z 5Z #v #v#vZ :V l05 55Z / 4$$If!vh5 55Z 5Z #v #v#vZ :V l05 55Z / 4$$If!vh5 55Z 5Z #v #v#vZ :V l05 55Z / 4$$If!vh5 55Z 5Z #v #v#vZ :V l05 55Z / 4$$If!vh5 55Z 5Z #v #v#vZ :V l05 55Z / 4Df Dropdown1$$If!vh5 55Z 5Z #v #v#vZ :V l05 55Z / 4$$If!vh5 55Z 5Z #v #v#vZ :V l05 55Z / 4$$If!vh5_ 55#v_ #v#v:Vl t)5_ 55/ /  / / vDText71vDText72vDText73~$$If!vh5_ 55#v_ #v#v:Vl t)5_ 55/ vDText74vDText75vDText76p$$If!vh5_ 55#v_ #v#v:Vl t)5_ 55vDText77vDText78vDText79p$$If!vh5_ 55#v_ #v#v:Vl t)5_ 55vDText80vDText81vDText82p$$If!vh5_ 55#v_ #v#v:Vl t)5_ 55vDText83vDText84vDText85p$$If!vh5_ 55#v_ #v#v:Vl t)5_ 55vDText86vDText87vDText88p$$If!vh5_ 55#v_ #v#v:Vl t)5_ 55@@@ NormalCJ_HaJmH sH tH @ A Heading 1J$ /p@ ,P !$`'h@&^h`#5B*CJOJ QJ \^J aJph\@\ "m9 Heading 2$<@& 56CJOJQJ\]^JaJ@ A Heading 5:$ /hp@ P !$`'@&#5B*CJOJ QJ \^J aJphDA@D Default Paragraph FontRi@R  Table Normal4 l4a (k(No List4@4 JHeader  !4 @4 JFooter  !j@j Table Grid7:V0.)@!. A Page NumberB@2 A Body Text1 ,p@ P !$`'#6B*CJOJ QJ ]^J aJphxQ@Bx A Body Text 31 ,p@ P !$`'B*OJ QJ ^J ph6U@Q6 i Hyperlink >*B*phHCbH Body Text Indenthx^h8Or8 CG Times OJQJ^JH@H T Balloon TextCJOJ QJ ^J aJFVF fFollowedHyperlink >*B* phN^N K& Normal (Web)dd[$\$ PJ nHtHNON "m9Text Times Rom 11 ^CJaJޓ8o z z z v z z z z z z z z z z z z z z 2)F0>=aDRW]b?pM{\&ޓ=  #  &?KLrs56f#$GHxy.W       ( ) a r ~&'NVgp$8L`t+?Sg{| 2FZ[o#789,-|8LMNOPXYZ`as!"4IJKL^rs/0Bas$*<DV\n/AKL^./Ay  J\fgy $ % & ' 9 j k l { '!(!:!T!f!!!!!!!!!"1"H"I"["v"w"x"y""""""""""###9#K#b#c#u########$$"$?$Q$d$e$w$$$$$$$$$%2%3%E%T%f%%%%%%%%%&&M&N&`&&&&&&&&&&&&&&&&&&&&&&k'l'~'''''''( (2(P(Q(c((((((((((())0)3)_)`)a)))*l*m********++&+'+;+O+c+d+x+y+++++++++,,,,1,E,Y,Z,\,],^,F-|-}---D.z.{....E/F/|/}////,0.0F0G00000`1a11"2b2223s33P4444>5555?6667777888999999:::::::;;<8=>=======>>(><>>>>>>>>>>>>???/????????????????@Ap?pJpLppppqqq0rirjr ssttuvyC{D{E{F{G{H{J{K{L{M{N{O{[{\{{{{{{{{{{{{{|| ||||||0|1|2|8|9|:|;|A|U|V|W|||||||+},}8}X}x}y}}}} ~/~}~~~~~~~~~!N~ʀҀ()IJ89:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^ijxy~Ӄԃ&';OPdey˄̄  !"#$%&'2nB͉ߊg‹\aʐN[rߓ)s)s)s))s))s)i)s)s)s)m1)s)U)s))s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)))))s)s)s))s))s)s))s)s)s)s)s)s)s)s)s)s))s)m1)k)k)k)k)k)k)k)k)k))s))s)s)s)s)s)s)s)s)s)s)s)s))s)s)s)U)s)))s)s))s))s))s))s)s)s)s)s)s)s 7s 7U 7s 7ss|s|s|sssssswss`s`ssssss jj|j|jjjjj`jjjjjjj|j|jjjjj`jjjj=jjj|j|jjjjj`jjjj=j|j|jjjjj`jjjj? 7s 7 7s 7 7s 7 7s 7 7s 7 7s 7s 7s 7)))s))s)s@9@96@96@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9q@9@9D@9__@9@9D@9b@9?9@9@9@9@9@9@9@9@9@9@9@9D@9b@9?9@9@9D@9b@9?9@9 @9@9 @9D@9@9?9@9h @9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9h @9 @9D@9@9?9@9h @9D@9@9?9@9h @9D@9@9?9@9h @9D@9@9?9@9h @9D@9@9?9@9h @9D@9@9?9@9h @9 @9D@9@9?9@9h @9 @9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9?9@9@9D@9@9C@9C@9C@9C@9@9?9@9@9D@9@9C@9C@9C@9C@9@9?9@9@9$@9q@9@9?9@9@9?9@9@9?9@9@9?9@9@9mD@9@9mD@9@9q@9@9@9@9?9)U)s)s))s)s))s))s)O sssKsKsZ s sssKs s sssKs s sssKs s sssKs)s)s)s))s)s))s)m1)s)s)s)))m1)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s))s))s)s))s)s)U)s)m1)s)s))sss1 ssesesesA s1 ssesss1 ssesss1 ssesss1 ssesss1 ssesss1 ssess)s)s))s)s)s)s))s)U)s)ss*sss*sss*sss*sss*sss*sss*sss*ss)U)s){)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s))s)s)s))s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)U)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s)s))s)s)s)s)s)s)s)s)s)s)s)s)s)s))s)s)s),r),r),r),r) ) )z) ),r) ),r),r),r) ),r),r),r+,r+,r+,r ,rV+,r+,r+,r ,rV+,r+,r+,r ,rV)))))))s)s)s)))))s)s)s)s)s)s)s)s)s)))))))))))))) s>ssss s s s s s>s>s>s>s>s>s>s>sssssssssssssss  s>s>s>ssss s s s>sss( s s>sss  s s>s>sssZ s s>s>s>sssssA  s>sssZ)))))))))))))))))))))))))))))))))))))))))))))))))))))s ssss s sss s sss s sss s sss s sss s sss)))))))))))))))))))))))))))))))))v:)v:)v:)))^)))v:)))))))v:)v:)^))v:))\ )v:)v:)v:))))v:)v:)v:)v:))j)j)j&?KLrs56f#$GHxy.W       ( ) a r ~&'NOPQRSTUVgp$8L`t+?Sg{| 2FZ[o#789,-|8LMNOPXYZ`as!"4IJKL^rs/0Bas$*<DV\n/AKL^./Ay  J\fgy $ % & ' 9 j k l { '!(!:!T!f!!!!!!!!!"1"H"I"["v"w"x"y"""""""""""###8#9#K#b#c#u##########$$"$>$?$Q$d$e$w$$$$$$$$$%2%3%E%T%f%%%%%%%%%&&M&N&`&&&&&&&&&&&&&&&&&&&&&&k'l'~'''''''''(( (2(O(P(Q(c((((((((((((((())/)0)1)3)_)`)a)))*l*m********++&+'+;+O+c+d+x+y+++++++++,,,,1,E,Y,Z,\,],^,F-|-}---D.z.{....E/F/|/}////,0.0F0G00000`1a11"2b2223s33P4444>5555?6667777888999999:::::::;;<8=>=======>>(><>>>>>>>>>>>>???/????????????????@Ap?pJpLppppqqq0rirjr ssttuvyC{D{E{F{G{H{J{K{L{M{N{O{[{\{{{{{{{{{{{{{|| ||||||0|1|2|8|9|:|;|A|U|V|W|||||||+},}8}X}x}y}}}} ~/~}~~~~~~~~~!N~ʀҀ()IJ89:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^ijxy~Ӄԃ&';OPdey˄̄  !"#$%&'2nB͉ߊg‹\aʐN[rۓߓ000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 0 0 0 0 0 0 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000 0 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 00 00 0 0,0 0 00 0 0,0 0 00 0 0,0 0 00 0 0,0 0 00 0 0,0 0 00 0 0 0 0 00 0 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 00 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 00 0 0 00 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 0 0,0000000000000000000000000000 000000 000000 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 0 0000000000000000000000000 0 0D 0D 0D 0D 0D 0D 0D 0D 0D 0 D 0 D 0 D 0 D 0 D000000 0 0R0000 0R0000 0R000 0R000 0R00 0R00000 0R00 0R0000 0R0000 0 R00 0 R000000 000000000000000000000000000000000000000000 0 0 0 00 00000000000 0 0000 0 0000 0 00000000p0p0p0p00q0q0q0q0q0q0q0q0q 0q0q0q0q0q0q0q0q0q0q0q0q0q0q0q00{ 0{ 0{ 0{ 0{0{0{0{0{0{ 0{0{0{0{0{0{0{0{ 0{0{0{0{0{0{0{0{ 0{0{0{0{0{0{ 0{0{ 0{0{0{ 0{0{ 0{ 0{0{0{0{ 0{ 0{ 0{ 0{0{0{ 0{ 0{ 0{ 0{0{0{ 0{0{ 0{ 0{ 0{0{0{ 0{0{0{ 0{0{0{ 0{ 0{0{ 0{ 0{ 0{ 0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{ 0{ 0{ 0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{0{ 0{ 0{ 0{ 0{ 0{0{ 0{ 0{ 0{ 0{ 0{ 0{0{0{ 0{ 0{0{ 0{ 0{0{0{0{ 0{ 0{ 0{0{0{0{0{0{0&0000000NO{|Z[78`a!"KL/0KL./  fg$ % j k '!(!!!!!H"I"x"y"""##b#c###$$d$e$$$2%3%%%%%M&N&&&&&k'l'''''( (P(Q(((((((()0)1)++c+d+++,,Y,Z,>>d>e>>>??W?X?????@CACiCjCCCCCCC DD6D7D_D`Doopp?ӱ00ӱ00թ00թ00ɱ00p0L0h>p0L0>p0L0>p0L0?p0L0p0L0p0L0p0L00p0L0hp0L0p0L0p0L0p0L0Hp0L0p0L0p0L0p0L0(p0L0`p0L0p0L0p0L0p0L0@p0L0dp0L0p0L0Ԅp0L0 p0L0Dp0L0|p0L0L0 MMMMMMMMMMMMMMMP0 - :TTf!"#X$0%%&'l(4)-0142 33>567889:;;;<==>?@ANB"CDFGH0KfMOQSV\X^adfhg2hh)jl`nFo(pքfR",/5:889:J;/Dz~NQRTUWXY[]_`befhijkmnopqsux| (-/:=?BEHPVL 4Xhfj!"$&0-01"2223K33445Q66)7Y7788/9994::;`;;;<m<<!=w==>\>>6??@@1@D@AZAAABBLB}BB^EFJGGH6IKOlRBVZv]aef(gglhiijm6nnn,o~oo"pfpZru>xzF~:‡ʋ$Di#R$$$R&/50k0D112b33455788 99:~::;?A@SABuBBCDbG1~OSVZ\^acdglrtvwyz{}~  %&')*+,.0123456789;<>@ACDFGIJKLMNOQRU}P'!-3HTZmy "2R^d3?Edpvy/?o{  & ) 9 l x ~  "$068DJLX^`lrt#)+7=?KQS_egsy| *02>DFRX[gmo{ !#/5z$* }Rbaq"2L\0@aq"*:DT\l/?L\/?y JZgw ' 7 { (!8!T!d!!!!!!!"/"I"Y"y""""""##9#I#c#s#######$ $?$O$e$u$$$$$$%3%C%T%d%%%%%%%&&N&^&&&&&l'|''''' (0(Q(a((((())))))))))** *,*2*X*d*j*++$+'+3+9+;+G+M+O+[+a+d+p+v+y++++++++++++++++++++,,,,,),/,1,=,C,E,Q,W,G-W-h-t-z-~--E.U.f.r.x.|..G/W/h/t/z/~///00$0*000@00001L1X1^111&262f2v22222223]5i5o5B6R6l6|666667'7_7o777|88N9^9o9{99999:Z:j:n;;;+<p<<<=6=> >&>(>4>:><>H>N>P>\>b>e>q>w>y>>>>>>>>>>>>>>>>>>>>?????'?-?/?;?A?C?O?U?X?d?j?l?x?~???????????????????r@@@/AtAAAB:B=BMBUBeBmB}BBBACMCSCUCaCgCjCvC|C~CCCCCCCCCCCCCCCCCCCD DDD D"D.D4D7DCDIDKDWD]D9RIR[RgRmRoRRTS`SfStSSSSSSSSSS TT,T8T>TVTfTTTUUU+U1UaUqU~UUUUUUUUUVV,V4V@VFVfVvVVVVVVVVVVWWWWWWWWWWWXX!X1X8XDXJX_XoXXX YYgYwYYYY ZZZ:ZJZZZZZZZZ'[7[_[o[x[[[[[[[[\\W\g\\\]] ],]2]4]D]____s```` aa#a3al2mYmwwxfxxxfyyyzzzz+˃уԃ $'39;GMP\beqwyÄɄ̄؄ބޓG G$FFFFFFFFFFFG$G$FFG$G FFG$FFG$G$FFG$FFFFG$FG$FFFFG$G$G G FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFG$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$G$FFG$FFFFFFFFFFFFFFFFFFG$FG$G$FG$G$FG$G$FG$G$G$FG$G$G$G$FG$FG$G$G$G$G$G$G$G$G$FG$G$G$XXXFFFFFFFFFFFFFFFFFFFFFFFFXXXG$G$G$G$FFFFFFFFFFFFFFG$FG$FG$G$G$G$G$G$FG$G$G$FG$G$G$G$G$G$G$FG$G$G$G$FFG$G$G$G$G$G$FG$G$G$G$FFG$G$FG$G$G$FG$FG$G$G$G$FG$G$G$G$G$G$G$XXXXXS$FFFFFFFFFFFFFFFFFF  P!!l  ,b$:no `nu?@V (     xA. `logoB&WLlineS`TS`T#" B S  ?ޓ *plCheck166Check169Text1Text2Text3Text4Text5Text6Text7Text8Text9Text10Text11Check3Check4Text13Text14Check157Check175Text69Text70Check63Text17Text21Check64Check170Text19Text20Check171Text68Text65Text66Text67Check66Text22Check67Text23Text24Text25Text26Check80Check81Check158Check172Text89Text90Text91Text92Text93Text94Text95Text96Text97Text98Text99Text100Text101Text102Text103Text104Text105Text106Text107Text108Text109Text110Text111Text112Text113Text114Text115Text116Text117Text118Text119Text120Text121Text122Text123Text124Text125Text126Text127Text128Text129Text130Text131Text132Text46Text47Text48Text49Text50Check159Check160Check173Check174Check37Check38Check39Text27Text28Check40Text29Text30Text133Text134Text135Text136Text137Text138Text139Text140Text141Text142Text143Text144Text145Text146Text147Text148Check70Text45Check71Check51Text38Check52Check53Text39Check54Check55Text40Check56Check57Check58Text41Check147Check148Check149Check150Text42Check155Text43Check151Check164Check165Check152Check153Check154Check161Check162Check68Text44Check69Check78Check79Text149Text150Text151Text152Text153Text154Text155Text156Text157Text158Text159Text160Text161Text162Text163Text164Text165Text166Text167Text168Text169Text170Text171Text172Check59Check60Check61Check62Text173Text174Text175Text176Text177Text178Text179Text180Text181Text182Text183Text184Text185Text186Check82Text51Check83Text52Check84Check85Check86Check87Check88Check156Text53Check89Check90Check91Text54Check92Check93Check94Check95Check96Check97Check98Text55Check99Check100Check163Check101Text56Text57Check102Check103Check104Check105Check106Check107Text58Check108Check109Check110Check111Text59Text60Check112Check115Text61Check113Check114Check116Text62Check117Text63Check118Check146Check119Check120Text64Check121Check122Check124Check128Check130Check137Check139 Dropdown1Text71Text72Text73Text74Text75Text76Text77Text78Text79Text80Text81Text82Text83Text84Text85Text86Text87Text88"In#S4ez0p  * m %9Mau,@Th} 3G\p${ ~S)))*!*Y*+(+<+P+e+z+++++++ ,,2,F,H-i--F.g.}.H/i///01000M11'2g2222^5C6m6667`77}8O9p999[:>)>=>Q>f>z>>>>>>>??0?D?Y?m???????>BVBnBBBCVCkCCCCCCCCD#D8DLD:R\RpRUSuSSSSS T-TWTTU UbUUUUUUV5VgVVVVVWWWWW X"X9X`XX YhYY Z;ZZZZ([`[y[[[\X\\]!]5]__t``a$aՃ(<Qfz̈́ߓ  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     (4[ 3eFw@ ' :   #7K_s*>Rfz 1EYn"6+c)))*3*k*%+:+N+b+w+++++++,,0,D,X,X-{--V.y..X/{//0+0A001_1172w2223p5S6}666(7p778_999:k:'>;>O>c>x>>>>>>>??.?B?V?k????????NBfB~BBTChC}CCCCCCC D!D5DJD^DJRnRRgSSSSSTT?TgTTU2UrUUUUU V-VGVwVVVVVWWWWWX2XKXpXXYxYYZKZZZZ8[p[[[[\h\\]3]E]__``a4a,҃%:Ncxʄ߄ߓ o \" ,  [U> V> d?!X> ?! Y> $@!Z> d@!    L ԏ     ̭ b c Tc e e |e *urn:schemas-microsoft-com:office:smarttags PostalCode9*urn:schemas-microsoft-com:office:smarttagsState:*urn:schemas-microsoft-com:office:smarttagsStreet;*urn:schemas-microsoft-com:office:smarttagsaddress8*urn:schemas-microsoft-com:office:smarttagsCity9*urn:schemas-microsoft-com:office:smarttagsplace 0m*.^d"$)<CV[nAJtAH y  9 A B I N X ^ b !!!r!{!!!!!!!1"9":"@""""## #!#*#,#6#K#W#X#a######$$$Z$c$$$$$$$%% %(%)%,%-%1%E%M%f%q%r%~%%%%%%%&'&)&L&`&e&j&p&&&'''''(((((2(<(=(E(F(N((((((((()))')))**%E0E_LhLqLzLMMMMxV|VWXXXJ[S[\\\\'`6`cdhhkmomppqqmrqrss2s)////J0O000d1j1t3|333Q4V444?5K5555>677N8X8r:~:N=P=BBbDmDDDX!X___```mrqrssxxIOđ͑Бܑ\_jqrȒɒ@ߓ:::::::::::::::::::::::::::::::::::::::::::::::Ls r pPas"4L^0Bas$*<DV\n/AL^ \g ' 9 { (!:!T!f!!!!1"I"["y""""""##9#K#c#u#######$"$?$Q$e$w$$$$$$%3%E%T%f%%%%%&`&&&&&&~''2(Q(((((())@)*+o3t3r::==BB(CACbDDPFzFHHyJJ9RR$ShS"TVTU4UVfVVWMX_XgYYY:ZZ[[\]V]X]]bbSgigoo p=p?pLpO{\{{{|A| ~/~~~~~)^'2gÎN[ܑړߓff1155xx llrr||55=)=)}:}:BBhChCbbWlWllZmmmmmnn~n~n6o6oQoQoooooߓb>42 ],&V\d042 !mb3 BA9L,I;#Mg7QS#JVlS^W[f'RNsdT}Wzƅ>r)}A%O}@*^`o(. ^`5hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hH^`o(. ^`5hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hH88^8`o(.^`. L ^ `L.  ^ `.xx^x`.HLH^H`L.^`.^`.L^`L.^`.^`.pp^p`.@ @ ^@ `.^`.^`.^`.^`.PP^P`.^`.^`.pp^p`.@ @ ^@ `.^`.^`.^`.^`.PP^P`.h^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hH^`.^`.pp^p`.@ @ ^@ `.^`.^`.^`.^`.PP^P`.h^`OJQJo(hHh^`OJ QJ ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^Jo(hHohPP^P`OJQJo(hH^`.^`.pp^p`.@ @ ^@ `.^`.^`.^`.^`.PP^P`.^`.^`.pp^p`.@ @ ^@ `.^`.^`.^`.^`.PP^P`.g7Q!mb3}Wzp ],b>\d0S^W[#JV%O}'RNs#M,I;r)} BA9|  @hh^h`OJQJ^Jo( `R                         p                                            F !Fw o,>kK>L_TWzZ{rYzVBZ2/VHbBQ%J,tKX'NOPQRSTUVp$8L`t+?Sg{| 2FZ[o#78OPXYZ`as!"4IJKL^rs/0Bas$*<DV\n/AKL^./Ay  J\fgy $ % & ' 9 j k l { '!(!:!T!f!!!!!!!!!"1"H"I"["v"w"x"y"""""""""""###8#9#K#b#c#u##########$$"$>$?$Q$d$e$w$$$$$$$$$%2%3%E%T%f%%%%%%%%%&&M&N&`&&&&&&&&&&&&&&&&&&&&&&k'l'~'''''''''(( (2(O(P(Q(c((((((((((((((())/)0)1)****++'+;+O+c+d+y++++++++,,,1,E,Y,Z,>====>>(><>P>d>e>y>>>>>>>>???/?C?W?X?l??????????(C5C@CACUCiCjC~CCCCCCCCCC DD"D6D7DKD_D`Doooo ppp6p!?!@NCNDNEhRhShThUhVhWhXYZ[\]c`ޓ@@@ @@@@@@@@@<@@"@$@&@*@,@.@`@@4@l@@D@F@H@J@L@N@P@R@@@V@@@Z@@@`@@@f@h@@@n@p@@@@@@@@@@@@@@@,@@0@@8@:@x@@P@Unknown!Information Technology & ServicesGz Times New Roman5Symbol3& z ArialY CG TimesTimes New RomanG5  hMS Mincho-3 fgE Californian FBA& Arial Narrow7 ArialMTQ Arial-ItalicMTArialC .PMingLiUe0}fԚ9PalatinoK,Bookman Old Style5& zaTahoma?5 z Courier New;Wingdings"qhsfzF }K }K `24dDDKK! 3QHP ?b 24Indiana University Purdue University at Indianapolissaxe!Information Technology & ServicesH          Oh+'0( T`    8Indiana University Purdue University at Indianapolissaxe Normal.dot$Information Technology & Services5Microsoft Office Word@d@f .@m@l'}՜.+,D՜.+,d  hp  R&SP KD' 5Indiana University Purdue University at Indianapolis TitleTH0H _PID_HLINKS_AdHocReviewCycleID_EmailSubject _AuthorEmail_AuthorEmailDisplayName_ReviewingToolsShownOnceABrpe<http://www4.od.nih.gov/oba/rac/guidelines_02/APPENDIX_C.htm7wb.http://www4.od.nih.gov/oba/rac/guidelines_02/_Section_IV-C-1-b-(1)._Majorpp_<http://www4.od.nih.gov/oba/rac/guidelines_02/APPENDIX_A.htm7w\.http://www4.od.nih.gov/oba/rac/guidelines_02/_Section_IV-C-1-b-(1)._Major5kY'http://www.research.luc.edu/complianceS&http://www.absa.org/resriskgroup.htmlOI6http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4/toc.htmRD:http://www4.od.nih.gov/oba/rac/guidelines/guidelines.htmlSG&http://www.absa.org/resriskgroup.htmlOID6http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4/toc.htmRDA:http://www4.od.nih.gov/oba/rac/guidelines/guidelines.htmlmfIBC/BHC stuffsaxe@iupui.eduAxe, Shawn L  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry FV*'Data 1TableWordDocument6SummaryInformation(DocumentSummaryInformation8CompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q